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Zusammenfassung
Die initialen immunologischen Prozesse, die zur Entwicklung autoimmuner
Lebererkrankungen führen, sind weitgehend unbekannt. Deshalb wurden in
dieser Arbeit die Antigenpräsentation, die Migration sowie der Phänotyp in
vivo aktivierter CD8 T-Zellen in der Leber anhand eines Mausmodells der
autoimmunen Hepatitis untersucht.
Es ist bekannt, dass nicht-professionelle antigenpräsentierende Zellen, wie
sinusoidale Leber-Endothelzellen aber auch Hepatozyten, naïve CD8 T-Zellen
aktivieren und so zu ihrer Toleranz oder Deletion beitragen können. In dieser
Arbeit konnte jedoch gezeigt werden, dass hepatische dendritische Zellen an
der Entstehung von CD8 Effektor-T-Zellen und an der Inflammation der Leber
beteiligt sind. Kupffer-Zellen dagegen nehmen im autoimmunen Kontext in der
Leber eine tolerogene Funktion ein.
Die in vivo in der Leber aktivierten CD8 T-Zellen zeigten spezifische Ober-
flächenmarker und ein ungewöhnliches Migrationsverhalten. So wurde zum
einen mit Neuropilin-1 ein weitgehend unbekannter Oberflächenmarker identi-
fiziert, zum anderen spricht die Expression von bekannten Markern, die den
Aktivierungstatus der CD8 T-Zellen definieren, für einen hybriden Phäno-
typ. Sie besitzen sowohl Charakteristika von naïven CD8 T-Zellen als auch
von Effektorzellen, eine Eigenschaft, die auch bei zentralen Gedächtniszellen
gefunden wird. In der Leber aktivierte CD8 T-Zellen können nicht nur pro-
inflammatorische Zytokine ausschütten und somit eine Inflammation in der
Leber auslösen, sondern sind außerdem in der Lage durch Lymphknoten zu
zirkulieren. Dagegen ist ihnen der Zugang zum Darm verwehrt, womit eine
direkte regulatorische Funktion im Darm ausgeschlossen werden kann. Obwohl
auf in der Leber aktivierten CD8 T-Zellen spezifische Adhäsionsmoleküle iden-
tifiziert wurden, existiert keine exklusive gewebespezifische Migration in die
Leber, wie sie etwa für im Darm aktivierte CD8 T-Zellen nachgewiesen wurde.
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Zusammenfassung
Im darmassoziierten lymphatischen Gewebe aktivierte CD8 T-Zellen akku-
mulieren in der Leber und tragen möglicherweise zur Schädigung der Leber im
Rahmen chronisch entzündlicher Darmerkrankungen bei.
Diese Arbeit trägt somit zum besseren Verständnis der Entstehung autoimmuner
Prozesse in der Leber bei.
xii
Summary
Initial immunological processes leading to autoimmune liver diseases are largely
unknown. Therefore this thesis analyzed the antigen presentation, the migration
as well as the phenotype of in vivo activated CD8 T cells in the liver by
employing a mouse model for autoimmune hepatitis.
It is known that non-professional antigen-presenting cells, such as liver sinu-
soidal endothelial cells as well as hepatocytes activate naïve CD8 T cells, which
leads to their tolerance or deletion. However, this thesis provides evidence that
hepatic dendritic cells are effective antigen-presenting cells, which contribute
to the induction of functional effector CD8 T cells in the liver and hepatitis.
In contrast, Kupffer cells have a tolerogenic role during autoimmune processes
in the liver.
CD8 T cells that were in vivo activated in the liver display specific surface
markers and unusual migration patterns. On the one hand an unknown surface
molecule Neuropilin-1 was identified, on the other hand expression of well-
known markers defining the activation-status of CD8 T cells suggests a hybrid
phenotype. They display characteristics of naïve and effector T cells, but also
aspects of central memory T cells. Liver-primed CD8 T cells do not only
produce pro-inflammatory cytokines leading to hepatitis, but they also retain
their ability to circulate through lymph nodes. However, they have no access
to the gut, which suggests that a direct regulatory function in the gut can be
excluded. Although specific adhesion molecules on CD8 T cells activated in the
liver were identified, no exclusive tissue-specific migration into the liver exists,
as was shown for CD8 T cells primed in the gut. CD8 T cells activated in the
gut-associated lymphoid tissue accumulate in the liver, in principle enabling
them to induce liver pathology in the context of inflammatory bowel disease.
Thus, the here described findings contribute to the understanding of initial
immunological processes in autoimmune liver diseases.
xiii
1 Introduction
1.1 The liver, its anatomy and function
The liver is the largest internal organ of the body and is essential for survival.
It has numerous functions including blood detoxification, bile production,
metabolism of nutrients, protein synthesis, and hormone excretion as well as
storage of vitamins, glycogen and minerals, to name only the most important.
Liver tissue is predominantly composed of parenchymal cells called hepato-
cytes. These cells are arranged as interconnected plates in hexagonal structures
that form the hepatic lobule. A lobule is defined by the central vein in the
center, and the portal tract – consisting of portal vein, hepatic artery, and bile
duct – located at the lobule periphery. The hepatocytes are separated by a
special capillary system – the sinusoids – lined by liver sinusoidal endothelial
cells.
The liver receives dual blood supply. Gut-derived blood, enriched in nutrients,
but also toxins and microbial products enter the sinusoids through the portal
vein, whereas oxygenated blood enters the liver through the hepatic artery.
From the portal tract, nutrient-rich and oxygenated blood is mixed within
the liver lobules and percolates through the sinusoids, where nutrients are
exchanged between blood and liver cells. The blood finally passes into the
central veins and returns to the body circulation (Abdel-Misih and Bloomston,
2010).
Hepatocytes account for the largest cell population in the liver. Other non-
parenchymal cell populations include liver sinusoidal endothelial cells (LSECs),
Kupffer cells (KCs), dendritic cells (DCs), hepatic stellate cells (HSCs) as
well as lymphocytes (Racanelli and Rehermann, 2006). Within the hepatic
lymphocyte population γδ-T cells, natural killer (NK) cells, and natural killer T
(NKT) cells are highly enriched.
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Whereas CD4 T cells are more abundant within blood lymphocytes, more
CD8 T cells are present in the liver (Norris et al., 1998; Tu et al., 2007).
All cells in the liver are continuously exposed to antigens from intestinal-
derived blood. A large number of these antigens are tolerated to avoid perma-
nent immune reactions, while other antigens, possibly pathogenic, are eliminated.
As a result, the liver has a unique local immune environment that maintains
self-tolerance while also responding to pathogens.
A remarkable feature of the liver is the spontaneous tolerance of transplanted
liver allografts. In animals, the liver may be tolerated without immunosupres-
sion (Calne et al., 1969; Houssin et al., 1980; Sugioka et al., 2001). Transplan-
tation of the liver can improve the tolerance and survival of a simultaneously
transplanted kidney in humans (Rasmussen et al., 1995; Lang et al., 1998). In
addition, liver-transplantation reverses the allograft rejection of pancreas and
skin in rodents (Wang et al., 1998; Kamada et al., 1981).
In summary, the liver is tolerant towards antigens itself, but also transfers
tolerance to other organs. Although the liver’s immunologic environment is
generally tolerogenic, some pathogens cause chronic inflammation. Autoimmune
liver diseases occur when the liver’s tolerance capabilities fail.
1.2 Breaking tolerance leads to autoimmunity
Central and peripheral tolerance
The immune system has developed several mechanisms to initiate an immune
response when attacked by pathogens while ignoring the body’s own cells and
harmless antigens. The latter mechanism is generally referred to as “tolerance”.
The first regulatory mechanism is named central tolerance and occurs during
lymphocyte development. T cells mature in the thymus and undergo several
positive and negative selection processes. Such selected T cells are tolerant to
self-antigens, but recognize foreign antigens bound to major histocompatibility
complex proteins (MHC) (Gallegos and Bevan, 2006). B cells, developing in the
bone marrow, also undergo negative selection and are deleted if their receptors
bind to self-antigens (Cornall et al., 1995).
Some lymphocytes escape central selection and have the potential to react to
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self-antigens in the periphery (Liu et al., 1995). Such self-reactive lymphocytes
are controlled by peripheral tolerance mechanisms. These include antigen igno-
rance, T-cell anergy, peripheral deletion of autoreactive T cells, and suppression
by CD4 Treg (regulatory CD4 T cells).
For instance, constant high-level antigen exposure of self-antigens leads to
deletion of lymphocytes (Miller et al., 1998). The absence of pro-inflammatory
cytokines or co-stimulatory signals during antigen presentation causes anergy
(Mondino et al., 1996). In addition, an anti-inflammatory cytokine milieu can
induce CD4 Treg, which are able to suppress activated lymphocytes or antigen-
presenting cells (APCs) by production of anti-inflammatory cytokines (Shevach,
2009). Furthermore, inhibitory molecules expressed by lymphocytes and APCs
lead to inactivation, apoptosis, and elimination of autoreactive lymphocytes
(Probst et al., 2005).
Autoimmunity
Tolerance mechanisms normally protect the body from immune reactions against
itself. However, self-reactive lymphocytes are found in the periphery in all
healthy individuals (Lohse et al., 1996). In some cases activation of these
cells, followed by reactions against self-antigens causes autoimmune diseases.
Autoreactive T cells and/or autoantibodies are involved in cellular damage
(Shlomchik, 2009). They recognize target-structures, destroy cells by cytolysis
or induce an inflammatory response.
In general, autoimmune diseases are divided into two categories: organ-
specific and systemic disorders. In organ-specific autoimmune diseases the
immune response is directed against a specific organ, such as the liver in
autoimmune hepatitis. A typical example of systemic autoimmunity is lu-
pus erythematosus, characterized by inflammation of multiple tissues due to
reactions against autoantigens found in every cell of the organism (Kotzin,
1996).
Autoimmune diseases develop spontaneously and their triggers are not known.
A combination of dysregulated immune response, genetic predisposition, and
environmental factors may promote autoimmunity. Genetic predisposition is
often associated with genes located in the human leukocyte antigen (HLA)
3
1 Introduction
locus, also known as major histocompatibility complex (MHC) (Thorsby and
Lie, 2005). MHC molecules present small peptides from foreign antigens and
self-antigens to T cells. Certain HLA alleles may influence the susceptibility to
autoimmune diseases, by promoting binding of specific peptide antigens. Insuffi-
cient presentation of self-antigens by HLA molecules to developing lymphocytes
in the thymus leads to the release of self-reactive lymphocytes into the periphery.
In addition, enhanced presentation of self-antigens may increase lymphocyte
activation in tissues (Simmonds and Gough, 2004). However, identical twins
demonstrate that genetic predisposition does not induce autoimmunity alone
and other factors have to be involved (Cooper et al., 1999). For example,
environmental factors, such as pathogens or drugs may trigger autoimmune
diseases. The immune system reacts to infections by releasing pro-inflammatory
cytokines. These cytokines can promote the activation of autoreactive T cells
or enhance the antigen presentation of self-antigens to lymphocytes, known as
bystander-activation (Wucherpfennig, 2001). “Molecular mimicry” is discussed
as a possible trigger for autoimmune diseases. Pathogens invading an organism
may present antigens with similarity to self-antigens. Production of autoanti-
bodies or autoreactive lymphocytes that cross-react with these self-antigens
may be the result of reactions against self (Wucherpfennig and Strominger,
1995).
1.3 Autoimmune liver diseases
Autoimmune diseases affecting the liver include autoimmune hepatitis (AIH),
primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC).
Neither cause nor pathogenesis of any of these diseases are known. As in
other autoimmune disorders, a combination of genetic background, gender, and
environmental factors are thought to trigger autoimmune liver disease. The
detection of specific autoantibodies as well as histological analyses are essential
to distinguish these disorders, which partially overlap (Rust and Beuers, 2008).
Autoimmune liver diseases are often accompanied by other disorders, such as
thyroid diseases, celiac disease, psoriasis, and rheumatoid arthritis (Efe et al.,
2012).
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1.3.1 Autoimmune hepatitis
AIH is a chronic liver disease characterized by an immunological reaction
against hepatocytes. Untreated, AIH can cause fibrosis and cirrhosis, resulting
in liver failure and death. Humans of all ages are affected, predominantly
women. Patients responding to immunosuppressive treatment have a good
prognosis and normal life expectancy. However, when diagnosis is delayed
in patients displaying progressive liver damage and who are unresponsive to
therapy may require liver transplantation (Manns and Vergani, 2009). The
risk of developing AIH depends on genetic predisposition. HLA alleles are
strongly associated with the disease, and other genes outside the HLA locus
are discussed (Tang et al., 2012). A typical histological finding in liver biopsies
are infiltrates of mononuclear cells, containing lymphocytes, plasma cells, and
macrophages (Krawitt, 2006). These inflammatory cells spread from the portal
areas, between and around hepatocytes into the periportal regions, thereby
destroying hepatocytes, leaving the characteristic “interface hepatitis” (Vergani
and Mieli-Vergani, 2008). Serological findings include elevated transaminases
(ALT, AST), IgG, and autoantibodies. Based on detection of autoantibodies
two types of AIH are distinguished. The autoantibodies ANA (antinuclear
antibody), SMA (smooth muscle actin), and SLA (soluble liver antigen) are
found in AIH type 1. The presence of the autoantibodies LKM (liver kidney
microsomal antigen) and LC1 (liver cytosol type 1) are characteristic for AIH
type 2, occurring mostly in children (Gossard and Lindor, 2012). The target
structures of LKM-1 and LC1 and the fact that cross-reaction occurs with
certain viruses, implies that molecular mimicry may trigger AIH type 2 (Manns
et al., 1991; Kerkar et al., 2003). Because autoantibodies are absent in 20% of
patients and are found also in other diseases, a pathogenic role is not assumed.
1.3.2 Primary biliary cirrhosis
PBC is a chronic liver disease that destroys the small intrahepatic bile ducts
resulting in defective bile flow (cholestasis), fibrosis, and cirrhosis. Women are
affected predominantly (Smyk et al., 2012). PBC frequently occurs in first-
degree relatives, and shows a high concordance rate in twins, which suggests
a genetic predisposition (Bogdanos et al., 2012). Patients diagnosed early
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who respond to ursodeoxycholic acid (UDCA) treatment, one of the secondary
bile acids, have an excellent prognosis. In contrast, patients with progressive
PBC usually require liver transplantation (Ishibashi et al., 2011). Genome-
wide association studies implicate that various alleles within the HLA locus,
but also genes involved in the regulation of immune responses, for instance
in interleukin-12 signaling, increase the susceptibility for PBC (Hirschfield
et al., 2009). Liver biopsies exhibit loss of bile ducts (ductupenia) as well
as infiltration of lymphocytes and macrophages. Serological findings include
elevated gamma-glutamyl transferase (γ-GT), elevated alkaline phosphatase
(ALP) and the detection of AMA (anti-mitochondrial antibody) (Hirschfield
and Gershwin, 2011). AMAs in PBC are directed against the E2 subunits of
the pyruvate dehydrogenase complex (PDC-E2) (Fussey et al., 1988). Regions
within this target antigen are also recognized by CD4 T cells and CD8 T cells
(Kita et al., 2002; Shimoda et al., 1998). Infectious organisms, for instance
Escherichia coli or Novosphingobium aromativorans are suggested to trigger
PBC through molecular mimicry (Fussey et al., 1990; Selmi et al., 2003).
1.3.3 Primary sclerosing cholangitis
PSC is a progressive liver disease of unknown cause, characterized by inflam-
mation and destruction of large intrahepatic and extrahepatic bile ducts. The
disease causes fibrosis, cirrhosis and acute liver failure. In contrast to other
autoimmune disorders, PSC affects men predominantly. Death or the decision
for liver transplantation occurs between 12 to 17 years after diagnosis (LaRusso
et al., 2006). PSC patients have a high risk of developing cholangiocarcinoma
and colorectal carcinoma (Saich and Chapman, 2008). Endoscopic retrograde
cholangiopancreatography (ERCP) is used to identify structural changes of the
bile ducts. Strictures can be dilated by endoscopy, but liver transplantation
remains the only life-extending treatment (Michaels and Levy, 2008). p-ANCA
autoantibodies (perinuclear antineutrophil cytoplasmic antibodies) are found
in 80% of PSC patients. Genetic susceptibility to PSC is conferred by specific
HLA-genes and non-HLA genes involved in bile homeostasis and inflammatory
pathways (Karlsen et al., 2010; Eri et al., 2004; Hov et al., 2010).
Up to 80% of PSC patients have inflammatory bowel disease (IBD) as the
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underlying condition (Broomé and Bergquist, 2006). In conjunction with PSC
the most often classified IBD is ulcerative colitis, but there is also an association
with Crohn’s disease (Loftus et al., 2005; Fausa et al., 1991). PSC can occur
years after colectomy, and colectomy before or during liver-transplantation
prevents the recurrence of PSC (Chapman et al., 1980; Alabraba et al., 2009).
In livers of PSC patients, atypical T cells are detected which express mol-
ecules usually found on gut-derived T cells (Hillan et al., 1999; Eksteen et al.,
2009). These findings led to the theory that these anatomically distinct diseases
are linked by the recruitment of gut-activated lymphocytes to the liver, where
they trigger an inflammatory response (Grant et al., 2001).
1.4 How T cells travel through the body
Mature naïve T cells patrol the body through blood vessels, lymphatic vessels
and secondary lymphoid organs (SLOs), including the spleen, peripheral lymph
nodes (pLN), and the gut-associated lymphoid tissue (GALT). Naïve as well as
activated lymphocytes leave the blood and extravasate into the lymph nodes
or into inflamed non-lymphoid tissues.
A process called “multistep adhesion cascade” involves rolling and teth-
ering of T cells, mediated by interactions between selectins and addressins
(Butcher, 1991). Equipped with chemokine receptors, T cells detect immobi-
lized chemokines on endothelial cells leading to their arrest (Cyster, 1999).
After signal transduction through the G-protein coupled chemokine receptors
integrins are activated and form high-affinity conformations. Binding of inte-
grins to adhesion molecules mediates the firm adhesion of lymphocytes before
they transmigrate into tissues (Luo et al., 2007).
1.4.1 Naïve T cells constantly patrol the secondary lymphoid organs
Naïve T cells enter the lymph nodes via specialized high endothelial venules
(HEV). They express L-selectin (CD62L) that binds to ligands, collectively
called peripheral node addressins (PNAds), such as GLyCAM-1 and CD34 (Ley
and Kansas, 2004). This interaction enables T cells to roll along endothelial
cells and enhances the probability of encountering the chemokines CCL19 and
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CCL21 displayed by the HEV. CCL19 and CCL21 interact with CCR7, a G
protein-coupled receptor, which mediates intracellular signaling, leading to
activation and conformational changes of nearby integrins (Förster et al., 2008).
Firm adhesion of lymphocytes in the pLN is mediated by binding of lymphocyte
function-associated antigen 1 (LFA-1; αLβ2) on T cells to intercellular adhesion
molecule 1 (ICAM-1). Low expression of α4β7 on naïve T cells and interaction
with mucosal addressin cell adhesion molecule (MAdCAM-1) promotes the
entry into the GALT (Bargatze et al., 1995). Lymphocytes transmigrate into
lymph nodes either taking a paracellular route through open junctions or a
transcellular route directly through endothelial cells (Cernuda-Morollon et al.,
2010). Lymphocytes not meeting their cognate antigen, leave the lymph node
via efferent lymphatics and return to the blood circulation.
1.4.2 Tissue-tropic T cells migrate into specific sites
Within the lymph nodes dendritic cells display antigens, sampled from inflamed
sites, to naïve T cells. Once they recognize their cognate antigen, naïve T cells
differentiate into effector cells and acquire a new repertoire of surface molecules,
which promote entry into inflamed sites. Effector T cells leave the lymph nodes,
return to the blood stream, and migrate preferentially into tissues that are
associated with the secondary lymphoid organs, in which they first encountered
their antigen. This process is known as tissue tropism (Kantele et al., 1999).
T cells that enter the gut or the skin are the best described examples of
tissue-specific migration of T cells. Lymphocytes activated by DCs in the
GALT upregulate the integrin α4β7 and the chemokine receptor CCR9 (Stagg
et al., 2002; Johansson-Lindbom et al., 2005). Retinoic acid, a metabolite of
vitamin A produced by intestinal DCs, is essential to induce the expression of
α4β7 and CCR9 on T cells (Iwata et al., 2004). CCR9 recognizes its ligand
CCL25, secreted by epithelial cells and lamina propria venules in the small
intestine (Wurbel et al., 2000; Kunkel et al., 2000). α4β7 binds to MAdCAM-1
expressed in the gut lamina propria venules (Berlin et al., 1993; Briskin et al.,
1997). Interactions between these molecules are required for T cells to enter the
small intestine, but it remains controversial if CCL25 and CCR9 are necessary
for migration into the colon (Papadakis et al., 2000; Wurbel et al., 2011).
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T cells activated by skin-derived DCs express cutaneous lymphocyte-asso-
ciated antigen (CLA), CCR10 and CCR4. Vitamin D3 or its metabolites
induce the expression of the chemokine receptor CCR10 (Sigmundsdottir et al.,
2007). Rolling of T cells on dermal endothelium is mediated by CLA binding
to E-selectin (CD62E) (Picker et al., 1991). CCL17 and CCL27, the ligands for
CCR4 and CCR10, are expressed by skin venules and keratinocytes, respectively
(Campbell et al., 1999; Homey et al., 2002). Interaction of these receptors and
molecules mediate the migration of tissue-tropic T cells to sites of cutaneous
inflammation.
The expression of tissue-specific molecules on T cells is not stable. Skin-
and gut-derived T cells can be reprogrammed to express alternative homing
receptors by restimulation with DCs from the reciprocal organ in vitro (Mora
et al., 2005).
1.5 T-cell migration into the liver differs from the multistep
paradigm
The liver contains a special microvasculature – the sinusoids – where lymphocyte
adhesion takes place (Wong et al., 1997). In contrast to other capillaries, the
discontinuous endothelial monolayer is fenestrated and lacks a basal membrane
(Wisse et al., 1996), allowing direct contact of T cells with the underlying
hepatocytes (Warren et al., 2006). Naïve and memory T cells frequently
migrate through the healthy liver, whereas the majority of activated T cells
are retained (Luettig et al., 1999; Mehal et al., 1999). The unique architecture
of the liver contributes to T-cell migration, which differs from the multistep
paradigm observed in lymphoid tissues and other organs.
Selectins and appropriate ligands are required for T cells to roll along en-
dothelial cells. In contrast, leukocyte rolling in the liver is independent of E-,
P-selectin, and L-selectin (Wong et al., 1997) and may not be required at all
given the small diameter of 5-7µm and the slow blood flow in the sinusoids
(MacPhee et al., 1995).
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Effector T cells infiltrating the inflamed human and murine liver in viral
hepatitis and autoimmune liver diseases express CXCR3 (Shields et al., 1999;
Curbishley et al., 2005; Kakimi et al., 2001; Zhang et al., 2011). Likewise, the
ligands for CXCR3, namely CXCL9, CXCL10 and CXCL11, are upregulated and
displayed by LSECs in the inflamed liver (Curbishley et al., 2005; Narumi et al.,
1997). Blocking CXCL9 and CXCL10 reduces the infiltration of T cells into the
liver in a murine model of hepatitis B (Kakimi et al., 2001). The development
of primary biliary cirrhosis (PBC) is delayed in CXCR3-deficient mice, but
infiltration of T cells into the liver is not entirely absent (Zhang et al., 2011).
Another chemokine receptor expressed by T cells in the inflamed liver is CXCR6
(Boisvert et al., 2003; Sato et al., 2005). Its ligand CXCL16, produced by
hepatocytes, LSECs and biliary epithelial cells in healthy and inflamed human
liver, promotes activation of β1-integrin and binding to VCAM-1 (Heydtmann
et al., 2005). Murine graft-versus-host disease (GVHD) is reduced when CXCR6-
deficient CD8 T cells are transferred (Sato et al., 2005). Yet another chemokine
receptor CCR5 and its ligands CCL3 and CCL4 are expressed in the inflamed
murine and human liver (Murai et al., 1999; Shields et al., 1999; Larrubia et al.,
2007). Blocking CCR5 reduces the infiltration of T cells in the liver in GVHD
(Murai et al., 1999). In contrast, T cell-mediated hepatitis in CCR5-deficient
mice leads to enriched T-cell infiltration and hepatitis that makes CCR5 an
unlikely candidate for migration into the liver (Moreno et al., 2005).
After T cells slow down and arrest, integrins and their ligands promote the
firm adhesion to endothelial cells. The adhesion molecules ICAM-1, ICAM-2
and VCAM-1 are constitutively expressed in the liver, and expression of ICAM-1
and VCAM-1 increase upon inflammation (Steinhoff et al., 1993; van Oosten
et al., 1995). αLβ2 (LFA-1), the binding partner of ICAM-1, mediates adhesion
of naïve and effector CD8 T cells to the liver (Bertolino et al., 2005; John and
Crispe, 2004; Sato et al., 2006). ICAM-1-mediated adhesion has been proposed
to be dependent on antigen presentation, because TCR-ligation regulates LFA-1
(John and Crispe, 2004; Bertolino et al., 2005). Antigen-independent adhesion
of activated CD8 T cells to the liver occurs via VCAM-1/α4-integrin (John
and Crispe, 2004), although α4-integrin is dispensable for the recruitment of
naïve T cells to the liver (Bertolino et al., 2005).
10
1 Introduction
Lymphocytes activated in the GALT express the integrin α4β7 and the
chemokine receptor CCR9, recognizing MAdCAM-1 and CCL25 in the intestinal
tract. MAdCAM-1, a typical gut-addressin, is upregulated in the liver in
various liver diseases, such as AIH, PSC, and PBC (Hillan et al., 1999). Both
α4β7/CCR9-positive T cells as well as CCL25 are detected in the inflamed
liver of patients suffering from PSC (Grant et al., 2001; Eksteen et al., 2004).
These T cells must be gut-derived, since neither dendritic cells nor stellate cells
derived from the liver are capable of imprinting the gut-specific phenotype
(Grant et al., 2001; Eksteen et al., 2009). However, it remains possible that
LSECs induce this phenotype (Neumann et al., 2012).
The vascular adhesion protein-1 (VAP-1) has enzymatic activity and may
play a role in the induction of MAdCAM-1 in the liver. Activation of VAP-1
by deamination of methylamine, present in the portal venous blood, induces
the expression of MAdCAM-1 on LSECs (Liaskou et al., 2011).
In summary, chemokine receptors and integrins play a role in T-cell infiltration
into the liver, but it is unknown whether they are regulated in the liver or
required for migration into the liver. A liver-specific adhesion molecule has yet
to be reported.
1.6 Antigen presentation and activation of T cells
Antigen presentation, a short overview
Adaptive immunity requires activation of T cells by antigen-presenting cells
(APCs). The antigen-specific T cell receptor recognizes antigens displayed by
major histocompatibility complex (MHC) molecules.
MHC class I (MHC-I) molecules, expressed by almost all nucleated cells,
present self-proteins but also exogenous intracellular antigens derived from
viral or bacterial infections to CD8 T cells. Antigens are degraded by cytosolic
and nuclear proteasomes. The resulting short peptides are translocated into
the endoplasmatic reticulum (ER) by transporter associated with antigen
presentation (TAP). In the ER peptides are loaded onto MHC-I and transported
via the Golgi complex to the cell surface, where the antigens are displayed to
CD8 T cells (Neefjes et al., 2011).
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In contrast to MHC-I molecules, MHC class II (MHC-II) molecules are
mainly expressed by professional APCs, such as DCs, macrophages, and B cells.
MHC-II expression can be induced by inflammatory stimuli in non-professional
APCs, including endothelial cells, epithelial cells and others. Ingested exogenous
antigens are taken up into phagosomal compartments that fuse with lysosomes.
In the resulting phagolysosomes, MHC-II molecules interact with peptides, and
the peptide-loaded MHC-II molecules are transported to the cell surface, where
antigens are displayed to CD4 T cells (Neefjes et al., 2011).
However, the general paradigm of presentation of endogenous and extracel-
lular antigens by MHC molecules has expanded in recent years. CD8 T cells
are usually activated by professional APCs. When APCs are not infected by
pathogens, an appropriate immunogenic answer would fail. Therefore profes-
sional APCs also load exogenous antigens onto MHC-I molecules, displayed
to CD8 T cells, a process called cross-presentation (Bevan, 1976; Kurts et al.,
2001). The theory that endogenous antigens are presented by MHC-I molecules
only, can be extended as well. Through autophagy, a process by which cells
remove damaged organelles, endogenous antigens are also delivered to MHC-II
molecules and displayed to CD4 T cells (Schmid et al., 2007; Nimmerjahn et al.,
2003).
Activation of T cells
The interaction of an MHC/antigen complex and the TCR is not sufficient
to differentiate T cells into effector cells. Co-stimulatory molecules, such as
molecules of the B7-family expressed by APCs, but also cytokines and adhesion
molecules are involved in enhancing TCR-mediated responses. A well described
example is CD28 expressed by T cells, which interacts with the B7 members
CD80 and CD86. Binding of these molecules results in stimulation of T-cell
activation (Chen, 2004). In addition, co-inhibitory molecules, such as CTLA-4
(cytotoxic T lymphocyte antigen 4) and PD-1 (programmed cell death 1), bind
the same B7 members, down-modulating the T-cell response (Probst et al.,
2005).
Activation of naïve CD8 T cells leads to differentiation into cytotoxic effector
cells (CTL). By secreting granzyme and perforin they specifically lyse self-
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infected target cells. Binding of Fas molecules to the target cell via Fas ligand
on the CTL leads to apoptosis of the infected cell. The secretion of IFN-γ
enhances the expression of MHC molecules on others cells, thereby enhancing
antigen presentation and the removal of pathogens (Zhang and Bevan, 2011).
CD4 T cells differentiate into various subsets of CD4 T helper cells (TH),
depending on the cytokine milieu and the strength of the interaction of the
TCR with antigen. They regulate the adaptive immune responses by secreting
cytokines, which activate or recruit target cells. TH1 cells are involved in
elimination of intracellular pathogens and secrete pro-inflammatory cytokines,
which enhance phagocytic activity, promote CD8 T-cell activation, and help
to generate memory T cells (Zhu et al., 2010). TH2 cells mediate host defense
against extracellular parasites and support the humoral response. By secreting
a battery of pro- and anti-inflammatory cytokines, they stimulate B-cell prolif-
eration and antibody production, but also dampen strong immune responses
(Zhu and Paul, 2010). CD4 Treg maintain the immunologic tolerance to self
and foreign antigens. They negatively regulate a variety of immune responses,
such as allergy or pathogen-induced inflammation (Sakaguchi et al., 2006).
Numerous other subsets, such as TH17 cells or TH9 cells are described and
reviewed in (Luckheeram et al., 2012).
1.7 T-cell activation within the liver
In general T cells are activated by professional APCs in the lymph nodes or
spleen and then migrate into non-lymphoid tissues. The liver is an exception to
this rule insofar as it is a site at which naïve T cells can be activated (Bertolino
et al., 2001). Animal models extended the understanding of immunological
processes in the liver, from which the most significant examples are introduced
in the following section.
One of the first studies of liver inflammation was based on repeated immu-
nization of mice with liver-proteins in Freund’s adjuvant leading to hepatitis.
The induced hepatitis could be transferred to healthy mice by injecting lym-
phocytes from diseased mice, providing evidence that T cells play a major role
in immune-mediated liver disease (Mori et al., 1985).
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The injection of the leptin concanavalin (Con)A into mice leads to acute
liver damage driven by CD4 T cells, KCs, and NKT cells, all of which produce
pro-inflammatory cytokines such as TNF-α and IFN-γ (Tiegs et al., 1992;
Schumann et al., 2000; Kaneko et al., 2000; Küsters et al., 1996). However,
this model represents a cytokine-mediated model for acute liver injury rather
than antigen-driven hepatitis.
Transgenic models of autoimmune hepatitis are based on the expression
of model antigens in the liver. Expression of allogenic MHC-I molecules on
hepatocytes and transfer of TCR-transgenic T cells results in activation of
naïve CD8 T cells within the liver, but these T cells have a shortened life-
span and are soon deleted (Bertolino et al., 2001; Limmer et al., 1998). In
contrast, the expression of the same alloantigen in the liver and in lymph
nodes results in effector CD8 T cells mediating hepatitis, suggesting that
efficient T-cell activation only occurs outside of the liver (Bowen et al., 2004).
However, a limitation of these models is that the antigen is not presented
by professional APCs within the liver. Another mouse model expressing the
glycoprotein 33 in the liver, an epitope of the lymphocytic choriomeningitis
virus (LCMV), is ignored by transferred antigen-specific T cells and tolerance
could be broken only by additional LCMV-infection (Voehringer et al., 2000).
TF-OVA mice, a model established in our laboratory, express the antigen
ovalbumin in hepatocytes (Derkow et al., 2007). Adoptive transfer of antigen-
specific naïve CD8 T cells induces transient hepatitis, a result confirmed by
other groups using different promoters or antigens (Buxbaum et al., 2008;
Zierden et al., 2010). In addition Zierden et al. crossed mice expressing the
influenza virus hemagglutinin (HA) in the liver with mice with expressing
HA-specific CD8 T cells. These mice developed spontaneous chronic liver
inflammation (Zierden et al., 2010).
Other animal models are based on the theory of “molecular mimicry”. For
example, infection of wild-type mice with an adenovirus expressing the human
cytochrome P450 2D6 (Ad-2D6) (an autoantigen in human AIH type 2) results
in chronic autoimmune-mediated liver damage (Holdener et al., 2008).
T cells in the portal tracts and in the sinusoids have contact to a variety of
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non-professional and professional APCs. Although various cell types in the
liver have the potential to activate T cells, the fate of these T cells depends on
the type of APC on which they were activated.
1.7.1 T-cell activation by non-professional hepatic APCs
Hepatocytes
The majority of cells in the liver are hepatocytes. They express MHC-I and
under inflammatory conditions upregulate MHC-II as well as the co-stimulatory
molecules CD80, CD86, and CD40. (Franco et al., 1988; Sacher et al., 2002).
T cells interact with hepatocytes through fenestrations of LSECs (Warren et al.,
2006). Hepatocytes activate naïve CD4 T cells and CD8 T cells in vitro, leading
to premature death or to TH2-polarization (Bertolino et al., 1999; Herkel et al.,
2003). The transgenic expression of allogenic MHC-I molecules on hepatocytes
results in activation of naïve CD8 T cells in vivo (Bertolino et al., 2001). These
T cells are dysfunctional, undergo apoptosis and die by a process that depends
upon expression of pro-apoptotic protein Bim and caspase 3 (Holz et al., 2008).
In contrast, the injection of an adeno-associated virus (AAV-OVA) vector into
mice, that localizes in hepatocytes, leads to functional CD8 T-cell activation,
but fails to activate CD4 T cells (Wuensch et al., 2006, 2010).
The majority of reports indicate that hepatocytes act as APCs, activate
naïve CD8 T cells, but induce tolerance rather than immunity. Maintaining
tolerance induction by hepatocytes has been recently proposed, by a process
called “suicidal emperipolesis”. Thereby autoreactive T cells invade hepatocytes
and are degraded by lysosomal proteolytic enzymes (Benseler et al., 2011).
Liver sinusoidal endothelial cells
LSECs are scavenger cells, clearing the blood from foreign molecules and
antigens (Smedsrod et al., 1990). They express low levels of MHC-II, CD80,
and CD86, all of which are downregulated by IL-10 (Knolle et al., 1998).
LSECs cross-present soluble antigens to naïve CD8 T cells in vitro and in
vivo (Limmer et al., 2000; Oppen et al., 2009). Such primed T cells fail to
induce a cytotoxic response and are tolerized, correlating with the expression
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of inhibitory molecule PD-L1 (programmed cell death 1 ligand 1) expressed
by LSECs (Limmer et al., 2000; Diehl et al., 2008). CD8 T-cell activation by
potent APCs is inhibited when co-cultured with LSECs (Schildberg et al., 2008).
CD4 T cells activated by LSECs in vitro fail to develop a TH1-phenotype, but
differentiate into CD4 T cells with regulatory function (Knolle et al., 1999;
Kruse et al., 2009). Contradictory to these results, LSECs were also reported
to be poor in stimulating T cells, to lack MHC-II as well as co-stimulatory
molecules (Katz et al., 2004), and to fail to activate antigen-specific CD4 T cells
in vitro (Derkow et al., 2011).
Overall, LSEC represent a population of non-professional APCs, which
contribute to liver tolerance.
Hepatic stellate cells
HSCs are located in the space of Dissé and store the majority of vitamin
A (Li and Friedman, 1999). Following liver injury they differentiate into
myofibroblasts, which induce liver fibrosis (Gressner and Weiskirchen, 2006).
Reports about HSCs acting as APCs are contradictory. Whereas HSCs were
shown to express MHC-I, MHC-II, and co-stimulatory molecules, other reports
found that they lack these molecules (Vinas et al., 2003; Ichikawa et al., 2011).
They activate antigen-specific CD4 and CD8 T cells as well as NKT cells,
leading to IFN-γ-secretion (Winau et al., 2007). In contrast, co-cultures of
HSCs with allogenic T cells induce CD4 Treg (Jiang et al., 2008; Wu et al.,
2012). Additionally, HSCs fail to activate T cells (Ichikawa et al., 2011). Instead
they act as bystander cells for DC-T-cell activation in generating CD4 Treg,
depending on retinoic acid (Dunham et al., 2013). In liver transplantation
HSCs contribute to immune tolerance by induction of T-cell apoptosis (Jiang
et al., 2013).
In summary, only a few reports support that HSCs act as APCs for T cells.
More likely they represent a cell population that mediates tolerance.
16
1 Introduction
1.7.2 T-cell activation by professional hepatic APCs
Kupffer cells
KCs are liver-resident macrophages located in the sinusoids (Wisse et al., 1996).
They phagocytose cell remnants and pathogens, eliminate toxic agents, and
play a vital role in liver-regeneration (Hirakata et al., 1991; Eipel et al., 2007;
Abshagen et al., 2008). The majority of KCs express F4/80 and different levels
of CD11b and CD68 (Lloyd et al., 2008; Kinoshita et al., 2010). In addition,
the expression of MHC-II and the co-stimulatory molecules CD80 and CD86
render KCs potential APCs (You et al., 2008).
In response to low concentrations of lipopolysaccaride (LPS), they secrete
IL-10 leading to reduced T-cell proliferation (Knolle et al., 1995). KCs are
weak stimulators of CD4 T cells. They inhibit proliferation of T cells initially
activated by DCs and interact with CD4 Treg thereby enhancing T-cell tolerance
(You et al., 2008; Breous et al., 2009).
However, in response to microbial signals, KCs antagonize the suppressive
activity of CD4 Treg and produce pro-inflammatory cytokines such as TNF-α
and IL-18 (Wiegard et al., 2005; Okamura et al., 1995; Lichtman et al., 1998).
IL-18 leads to activation of NK cells and NKT cells in the liver, while TNF-α
contributes to concanavalin A-mediated hepatitis in mice (Schumann et al.,
2000; Dao et al., 1998).
Overall, KCs have tolerogenic but also immunogenic properties, depending
on signals present in the liver.
Hepatic dendritic cells
Hepatic DCs are located in the periportal areas and in the sinusoids (Watanabe
et al., 2007). Multiple populations of DCs exist in the murine and human liver.
Depending on their origin, myeloid (mDC) and plasmacytoid (pDCs) DCs are
distinguished by expression of different levels of CD11c (Lian et al., 2003).
mDCs in the murine liver express CD11c and CD11b, while human mDCs are
additionally defined by BDCA-1 expression. They secrete anti-inflammatory
cytokines mediating the expansion of CD4 Treg and TH2 cells (Chen et al.,
2009; Goddard et al., 2004; Bamboat et al., 2009).
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Murine hepatic pDCs are B220-positive, express low levels of CD11c, and
secrete anti-inflammatory cytokines, mediating antigen-specific T-cell suppres-
sion and induction of CD4 Treg (Lian et al., 2003; Goubier et al., 2008; Matta
et al., 2012). In contrast, when being activated, pDCs are effective APCs and
activate NK cells, NKT cells as well as antigen-specific CD8 T cells (Kingham
et al., 2007). Little is known about human hepatic pDCs and their potential to
activate T cells, but they may contribute to liver transplant tolerance (Gupta
et al., 2009).
The murine liver contains two subpopulations of DCs not found in the human
liver. CD11cCD8α-positive DCs are strong T-cell activators and produce pro-
inflammatory cytokines (O’Connell et al., 2000, 2003). Another subset, called
“natural killer DCs,” characterized by markers of DCs and NK cells (CD11c,
NK1.1), secrete IFN-γ, lyse tumor cells, and induce antigen-specific T-cell
activation (Pillarisetty et al., 2005).
Taken together, the liver contains heterogeneous populations of DCs. The
majority of liver DCs are weak activators of T cells, but some subsets may
induce immunity. It remains unclear whether hepatic DCs contribute to T-cell
activation in the liver, mediating hepatitis.
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1.8 Aims of the Study
Studies of T-cell priming in the liver have led investigators to assume that
non-professional APCs such as LSECs, but also hepatocytes induce tolerance
and possibly apoptosis and deletion of T cells. However, professional APCs
such as DCs and macrophages may influence the differentiation and the fate of
T cells in the liver. Therefore, we hypothesized that hepatic DCs and KCs, the
liver-resident macrophages, play a pivotal role in T-cell activation in the liver.
To test this hypothesis, liver inflammation was induced in a mouse model of
autoimmune hepatitis, in which a model antigen is expressed in the liver. In
addition, DCs and KCs were selectively depleted, and it was analyzed whether
they are capable of activating autoreactive naïve CD8 T cells mediating liver
inflammation in vivo.
The liver is a site of T-cell activation, but little is known about the migratory
properties of liver-primed T cells. Activated T cells that enter the liver may
originate from other organs such as the gut. Therefore, several questions
arise regarding the migration of liver-activated and gut-activated T cells. Do
liver-primed T cells display tissue-tropic migration as known for gut-derived
T cells? Do they migrate to other organs such as the gut? Conversely, do
T cells initially activated in the gut-associated lymphoid tissue migrate to the
liver where they are retained because they are activated? What happens if
they encounter their cognate antigen in the liver? By employing an in vivo
migration assay, this study intended to determine the migratory patterns of
CD8 T cells primed by the same antigen in the small intestine or in the liver. In
addition, differentially activated T cells were tested for their migration towards
their cognate antigen expressed in the liver or small intestine.
Activation of T cells in the liver and gut likely induces different phenotypes,
characterized by a distinct repertoire of surface molecules. A specific hom-
ing receptor for the liver has not been reported yet. Therefore, this study
intended to compare the phenotype of liver-and gut-primed T cells. Of the
two T-cell populations, activation markers, inhibitory molecules as well as
adhesion molecules were characterized, with the aim of identifying markers
that distinguish liver-primed T cells from T cells activated in other organs.
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2 Materials and Methods
2.1 Mice
TF-OVA mice express the antigen OVA139-385 fused to the transferrin-recep-
tor under the transferrin-promoter (TF) in hepatocytes (Derkow et al., 2007).
iFABP-OVA mice express the antigen OVA138-386 under control of the in-
testinal fatty acid-binding protein promoter (iFABP) in enterocytes. Mice were
provided by Prof. Lefrançois (Vezys et al., 2000).
CD11cDTR mice express the simian DTR (diphtheria toxin receptor) fused
to GFP (green fluorescent protein) under control of the murine CD11c promoter
(Jung et al., 2002) and were provided by the German Rheumatism Research
Center Berlin.
TF-OVA×CD11cDTR mice were generated by crossing TF-OVA mice to
CD11cDTR mice. For experiments the F1 generation was employed.
OT-I mice express a transgenic TCR (Vα2Vβ5) specific for the H2-Kb-
restricted peptide OVA254-267 (Hogquist et al., 1994). Mice were provided
by Prof.Blankenstein.
All lines were bred under specific pathogen free conditions in the Research
Institute for Experimental Medicine, Charité (FEM). Wild-type mice (C57Bl6J)
were purchased from the FEM. All animal experiments were approved by the
State Office of Health and Social Affairs, Berlin.
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2.2 Antibodies
Table 1: Antibodies for flow cytometry. All anti-mouse antibodies were pur-
chased from the following companies: 1 eBioscience, San Diego, USA, 2 BioLegend,
San Diego, USA, 3 BD Bioscience, Heidelberg, Germany, 4 R&D Systems, Min-
neapolis, USA.
Name Clone Isotype
αL 1 M17/4 Rat IgG2a,κ
α4 2 9C10 (MFR.B) Rat IgG2a,κ
α6 2 GoH3 Rat IgG2a,κ
αV 2 RMV-7 Rat IgG1,κ
α4β7 2 DATK32 Rat IgG2a,κ
β1 2 HMβ 1-1 Armenian Hamster IgG
β2 1 M18/2 IgG2a,κ
CD11b 1 M1/70 Rat IgG2b,κ
CD11c 1 N418 Armenian Hamster IgG
CD16/CD32 1 93 Rat IgG2a,λ
CD200 2 OX-90 Rat IgG2a,κ
CD25 1 PLS 1.5 Rat IgG1,λ
CD62L1 MEL-14 Rat IgG2a,κ
CD44 1 IM7 Rat IgG2b,κ
CD69 3 H1.2F3 Armenian Hamster IgG
CD8a 3 53-6.7 Rat IgG2a,κ
CCR7 1 4B12 Rat IgG2a,κ
CCR9 2 CW-1.2 Mouse IgG2a,κ
CXCR3 2 CXCR-173 Rat IgG2a
CXCR6 4 221002 Rat IgG2b
F4/80 1 BM8 Rat IgG2a,κ
GzmB 3 GB11 Mouse IgG1,κ
IFN-γ 1 XMG 1.2 Rat IgG1,λ
Ly-6C 2 HK 1.4 Rat IgG2c,κ
PD-1 1 J43 Armenian Hamster IgG
Vα2 TCR 3 B20.1 Rat IgG2a,κ
21
2 Materials and Methods
Table 2: Antibodies for immunohistochemistry. All antibodies were purchased
from the following companies: 1 BioLegend, San Diego, USA; 2 Abcam, Cambridge,
UK; 3DAKO, Glostrup, Denmark; 4 eBioscience, San Diego, USA; 5 Invitrogen,
Carlsbad, USA; 6Dianova, Hamburg, Germany.
Primary antibodies Clone Conjugate
Rat anti-mouse ICAM-1 1 YN1/1.7.4 Alexa Fluor 488
Rat anti-mouse MadCam-1 1 Meca-367 purified
Rat anti-mouse VCAM-1 1 429 (MVCAM.A) purified
Rabbit anti-mouse Laminin 2 polyclonal purified
Rabbit anti-human CD3 3 polyclonal purified
Rat anti-mouse F4/80 4 BM8 purified
Secondary antibodies
Donkey anti-rat IgG 5 polyclonal Alexa Fluor 488
Donkey anti-rat IgG 5 polyclonal Alexa Fluor 555
Donkey anti-rat IgG 6 polyclonal Biotin
Donkey anti-Rabbit IgG 6 polyclonal Biotin
2.3 Reagents and chemicals
Media, buffer & supplements
β-mercaptoethanol Sigma-Aldrich, Steinheim, Germany
Bovine serum albumin (BSA) Sigma-Aldrich, St. Louis, Germany
Dulbecco’s
Phospate-buffered saline (PBS)
PAA Laboratories, Pasching, Austria
Fetal calf serum (FCS) Biochrom AG, Berlin, Germany
L-glutamine Life Technologies, Carlsbad, USA
continued on next page . . .
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Penicillin/streptomycin
(10,000 U, 10 mg/ml)
Biochrom AG, Berlin, Germany
RPMI Media 1640 Life Technologies, Carlsbad, USA
Staining reagents
Carboxyfluorescein succinimidyl
ester (CFSE)
Life Technologies, Carlsbad, USA
4’,6-diamidino-2-phenylindole
(DAPI)
Roche Applied Science, Penzberg, Ger-
many
Eosin Merck, Darmstadt, Germany
Haematoxylin Merck, Darmstadt, Germany
Propidium iodide (PI) Sigma-Aldrich, Taufkirchen, Germany
Trypan blue Biochrom AG, Berlin, Germany
Reagents for cell stimulation
Brefeldin A Sigma-Aldrich, Taufkirchen, Germany
Ionomycin Sigma-Aldrich, Taufkirchen, Germany
Phorbol 12-myristate 13-acetate
(PMA)
Sigma-Aldrich, Taufkirchen, Germany
Protein Transport Inhibitor Cock-
tail
eBioscience, San Diego, USA
Saponin Sigma-Aldrich, Taufkirchen, Germany
SIINFEKL OVA257-264 Institute Biochemistry, HU Berlin
Histology
Formaldehyde
solution 4% buffered (pH 6.9)
Herbeta Arzneimittel, Berlin, Germany
Kaisers glycerol gelatin Merck, Darmstadt, Germany
ParaplastPlus McCormick Scientific, St. Louis, USA
Pro Taqs Clear Quartett, Berlin, Germany
Roti-Histol Roth, Karlsruhe, Germany
Tissue-Tek Compound Sakura Finetek, Torrence, USA
Liposome-preparation
Cholesterol Avanti Polar Lipids, Alabaster, USA
continued on next page . . .
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Clodronic acid salt Gift from Roche Diagnostics,
Mannheim, Germany
L-α-Phosphatidylcholine Avanti Polar Lipids, Alabaster, USA
Enzymes
Collagenase Type IV Sigma-Aldrich, Taufkirchen, Germany
DNase I Sigma-Aldrich, Taufkirchen, Germany
Proteinase K Sigma-Aldrich, St.Louis, USA
Cell separation
Easycoll (1.124 g/ml) Biochrom AG, Berlin, Germany
Nycoprep Axis-Shield, Oslo, Norway
Reagents for DNA & RNA
Agarose Serva, Electrophoresis GmbH, Heidel-
berg, Germany
Chloroform Merck, Darmstadt, Germany
RNApro Solution MP Biomedicals, Illkirch, France
TRIzol Life Technologies, Carlsbad, USA
100bp Plus DNA ladder Invitrogen, Karlsruhe, Germany
Other chemicals & reagents
Acetic acid Merck, Darmstadt, Germany
Ammonium chloride (NH4Cl) Merck, Darmstadt, Germany
Sodium [51Cr] chromate GE Healthcare, Munich, Germany
Dimethyl sulfoxide (DMSO) IC-Biochemicals, Ohio, USA
Diphtheria toxin Sigma-Aldrich, Taufkirchen, Germany
Ethanol Avantor Performance Materials, Deven-
ter, Netherlands
Ethylenediaminetetraacetic
acid (EDTA)
Merck, Darmstadt, Germany
Glycerol Sigma-Aldrich, St.Louis, USA
Potassium bicarbonate (KHCO3) Merck, Darmstadt, Germany
2-Propanol Merck, Darmstadt, Germany
Sodium chloride (NaCl) Merck, Darmstadt, Germany
continued on next page . . .
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Sodium dodecyl sulfate (SDS) Roth, Karlsruhe, Germany
TRIS Base Calbiochem, La Jolla, USA
2.4 Buffers, media and solutions
Name Ingredients
Digestion medium RPMI 1640
10% FCS (v/v)
0.05% Collagenase Type IV
Erylysis buffer, pH=7.3 150mM NH4Cl
1mM KHCO3
0.1mM EDTA
PBS/BSA PBS
0.5%BSA
2mMEDTA
PBS/FCS PBS
1%FCS
RPMI complete RPMI 1640
10% FCS (v/v)
2mM L-glutamine
100U/ml
penicillin/streptomycin
50µM β-mercaptoethanol
TAE buffer, pH=8 40mM Tris
1mM EDTA
20mM acetic acid
Tail lysis buffer, pH=8.5 100mM Tris
10mM EDTA
200mM sodium chloride
0.2% SDS
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2.5 Kits
Product Company
CD11b Micro Beads Miltenyi, Bergisch Gladbach, Germany
CD11c Micro Beads Miltenyi, Bergisch Gladbach, Germany
CD8+ T Cell Isolation Kit Miltenyi, Bergisch Gladbach, Germany
Dako Detection System, AP/Red Dako, Glostrup, Denmark
ENZO RNA Transcript Labeling
Kit
Affymetrix, Santa Clara, USA
FastRNA Pro Green Kit MP Biomedicals, Illkirch, France
GeneChip 3´IVT Express Kit Affymetrix, Santa Clara, USA
Pellet Paint Co-Precipitant Novagen, Madison, USA
Red Load Taq Master Jena Bioscience, Germany
RNeasy Mini Kit Qiagen, Hilden, Germany
SsoFast EvaGreen Supermix Bio-Rad Laboratories, Hercules, USA
SuperScript III Reverse Transcrip-
tase KIT
Life Technologies, Carlsbad, USA
2.6 Equipment
Centrifuges
Centrifuge 5415R Eppendorf, Hamburg, Germany
Rotina 420R Hettich, Tuttlingen, Germany
SIGMA 2K15 Braun Biotec, Melsungen, Germany
Incubators
Incubator C2000 Labotect, Göttingen, Germany
Thermomixer compact Eppendorf, Hamburg, Germany
Thermoshake Gerhardt, Königswinter, Germany
Waterbath Julabo U3 Julabo, Seelbach, Germany
continued on next page . . .
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Flow cytometer & cell sorter Becton Dickinson, Heidelberg, Germany
FACSCalibur flow cytometer
FACSCanto II flow cytometer
FACSAria I cell sorter
FACSAria II cell sorter
Equipment for histology
Cryostat 2800 Frigocut E Reichert-Jung, Nussloch, Germany
Embedding station Microm, Walldorf, Germany
Hypercenter XP Tissue Processor Shandon, Frankfurt, Germany
Microtome HM355S Microm, Walldorf, Germany
Microscopes Carl Zeiss, Jena, Germany
AxioImager Z1 microscope & Ax-
ioCam MRm
Axiophot & AxioCamHRc
Axiovert 25
MACS Separation Miltenyi, Bergisch Gladbach, Germany
MACS Multistand
MidiMacs Separation Unit
MiniMacs Separation Unit
LS Column
MS Column
Equipment for DNA & RNA
ABI Prism 7500 Sequence Detec-
tion System
Foster City, Applied Biosystems, USA
Agarose Gel Electrophoresis Sys-
tems
Bio-Rad Laboratories , München, Ger-
many
Agilent 2100 Bioanalyzer Agilent Technologies, Waldbronn, Ger-
many
Electrophoresis power supply Consort, Turnhout, Belgium
GeneChip Fluidics Station 450 Affymetrix, Santa Clara, USA
GeneChip Hybridization Oven 640 Affymetrix, Santa Clara, USA
continued on next page . . .
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GeneChip Scanner 3000 Affymetrix, Santa Clara, USA
NanoDrop ND-1000 NanoDrop Technologies, Wilmington,
Germany
Robo Cycler Gradent 96 Stratagene, La Jolla, USA
Thermocycler GeneAmp PCR
System 96000
PerkinElmer, Waltham, USA
UV-transilluminator Bioblock Scientific, Illkirch, France
Benchtop homogenizer MP Biomedicals, Santa Ana, USA
Other Equipment
Clean bench LaminAir 2448 Heraeus Instruments, Hanau, Germany
Wizard γ-counter Wallac, Turku, Finland
Sonorex sonicator Bandelin, Berlin, Germany
2.7 General consumables
Tubes
PCR-Softtubes Biozym, Oldendorf, Germany
15 / 50ml Polypropylene tubes BDFalcon, Bedford, USA
5ml Polystyrene tubes BDFalcon, Bedford, USA
1.5 / 2ml Reaction tubes Eppendorf, Hamburg, Germany
1.5 / 2ml Reaction tubes Sarstedt, Nümbrecht, Germany
Filter
Filter 70µm BDFalcon, Bedford, USA
Pre-Separation Filter, 30 µm Miltenyi, Bergisch Gladbach, Germany
Bottle-Top-Filter Nalgene, Rochester, USA
Tips & pipets
5 / 10 / 25ml cell-culture pipets BDFalcon, Bedford, USA
Sterilized Filter Tips Biozym, Oldendorf Germany
Tips Sarstedt, Nümbrecht, Germany
For histology
continued on next page . . .
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Capillary Gap(microscope slide) Dako, Glostrup, Dänemark
Coverslip (24 x 32mm) Menzel-Gläser, Braunschweig, Germany
Disposable Microtome Blades Typ
R 35
Feather, Osaka, Japan
SuperFrost Plus Coverslip Langenbrinck, Emmendingen, Germany
Tissue-Tek cassettes Langenbrinck, Emmendingen, Germany
Other consumables
Hematocrite-Capillaries Hettich, Tuttlingen, Germany
Neubauer counting chamber LO-Laboroptik GmbH, Friedrichsdorf
Set of instruments Aesculab AG, Tuttlingen
Plasmatube (Lithium-Heparin) Kabe Labortechnik, Nümbrecht, Ger-
many
Syringes & cannulas, Discardit,
Microlance
BD, Heidelberg, Germany
96-well plates BDFalcon, Bedford, USA
2.8 Primer
Table 3: Primer for genotyping by PCR. Primer were generated by ABI Primer
express 2.0 software and synthesized by TIPMolbiol company.
Name Sequence Fragment
TF-OVA F: 5’-CAAGCACATCGCAACCA-3’R: 5’-GCAATTGCCTTGTCAGCAT-3’ 480 bp
iFABP-OVA F: 5’-GCCATCACACTTGACCCTAA-3’R: 5’-TCAGGCAACAGCACCAACAT-3’ 608 bp
CD11cDTR F: 5’-GCCACCATGAAGCTGCTGCCG-3’R: 5’-TCAGTGGGAATTAGTCATGCC-3’ 625 bp
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Table 4: Primer for qRT-PCR. Primer were generated by ABI Primer express
2.0 software and synthesized by TIPMolbiol company.
Name Sequence
Rpl4 F: 5’-GTGGGCATGTGGGCCGTTTCT-3’R: 5’-GCGATGAATCTTCTTGCGTGGTGC-3’
Icam-1 F: 5’-AGCCTCCGGACTTTCGATCTT-3’R: 5’-AGAGGCAGGAAACAGGCCTT-3’
Madcam-1 F:5’-CCCTACCAGCTCAGCAGAGGACA-3’R: 5’-ACCCGGGCTACACCCTCGTC-3’
Vcam-1 F: 5’-GGGGGCCAAATCCACGCTTGT-3’R: 5’-AGGGAATGAGTAGACCTCCACCTGG-3’
2.9 Software
BDFACSDiva Software, BDFACSCellquest Software, Microsoft Excel for
Mac, ImageJ, Prism 5 for Mac, Photoshop CS6, Genes@work, Axio Vision,
Latex, Citavi, DAVID (Database for Annotation, Visualization and Integrated
Discovery).
30
2 Materials and Methods
2.10 Primary cell isolation from mouse tissue
2.10.1 Isolation of cells from lymph nodes and spleen
Lymph nodes (inguinal, superficial cervical, brachial, axillary, mesenteric,
lumbar, caudal, hepatic) and spleen were collected and passed through a nylon
cell strainer (70µm) with PBS/1%FCS. After centrifugation at 500 x g, 5min,
erythrocytes were lysed using an erylysis buffer followed by an additional
washing step (500 x g, 5min, 4◦C). Cells were kept at 4◦C in PBS/1%FCS for
further experiments.
2.10.2 Isolation of non-parenchymal cells from the liver
To isolate T cells from liver tissue for flow cytometry or to proceed with sections
for microscopy, livers were perfused with PBS. After cannulation of the hepatic
portal vein and perfusion with 10ml PBS, the liver was dissected from the
abdomen and the gallbladder removed.
In order to yield higher frequencies of T cells, or to isolate dendritic cells
and Kupffer cells, livers were perfused with 10ml digestion medium (RPMI,
containing 0.05% (w/v) collagenase IV). The liver was removed from the
abdomen, sliced in 10ml digestion medium and shaked in an incubation chamber
(20min, 200 rpm, 37 ◦C).
Livers were passed through a nylon mesh (70µm), followed by centrifugation
to remove hepatocytes and cell debris (50 x g, 3min, 4◦C). The supernatant was
transferred into a new tube, pelleted (500 x g, 5min, 4◦C), and erythrocytes were
lysed followed by an additional washing step (500 x g, 5 min, 4◦C). Thereafter,
cells diluted in 40% Percoll were overlaid on a 70% Percoll solution and
centrifuged at 1,000 x g, 20min, RT. Recovered cells from the interface were
washed (500 x g, 5min, 4◦C), counted, and kept at 4◦C in PBS/1%FCS for
further analysis.
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2.11 Isolation of cell-subsets by magnetic cell separation
(MACS)
2.11.1 Isolation of naïve OT-I CD8 T cells
T cells were purified from the spleen and lymph nodes of OT-I mice as described
(section 2.10.1). CD8 T cells were isolated by depletion of non-CD8+T cells using
the CD8α+T Cell Isolation Kit (Miltenyi Biotec) according to manufacturer’s
instructions. Naïve OT-I CD8 T cells were identified based on expression of
the markers Vα2, CD8 and CD69, using flow cytometry. Naïve T cells with
purity higher than 95% were used in further experiments.
2.11.2 Enrichment of dendritic cells and macrophages
Non-parenchymal cells from the liver and spleen were isolated as described (sec-
tion 2.10.2). Dendritic cells were enriched by positive selection of CD11c+ cells
using CD11c MicroBeads (Miltenyi). In order to enrich macrophages, CD11b
MicroBeads (Miltenyi) were used according to manufacturer’s instructions.
2.12 Isolation of liver-activated and gut-activated OT-I
CD8 T cells
Naïve OT-I CD8 T cells were isolated as described (section 2.11.1), labeled with
the cell tracker CFSE and injected into TF-OVA and iFABP-OVA mice. After
three days, proliferated CFSE+CD8 T cells activated by liver-derived antigen
were isolated from livers of TF-OVA mice (section 2.10.2) and purified by
subsequent fluorescence activated cell sorting. OT-I CD8 T cells were referred
to as “liver-activated T cells.”
OT-I CD8 T cells activated by small intestine-derived antigen were isolated
from mesenteric lymph nodes of iFABP-OVA mice (section 2.10.1) and sorted
likewise for CFSE+CD8 T cells. OT-I CD8 T cells were referred to as “gut-
activated T cells.”
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2.13 Determination of cell numbers
10µl of the cell suspension was diluted with trypan blue solution and transferred
to a Neubauer counting chamber. Living cells (not stained blue) were counted
in four outer quadrants and calculated as followed:
cells
ml =
counted cells
4 × dilution factor× 10
4
2.14 In vivo experiments
2.14.1 Adoptive transfer of T cells
Naïve OT-I CD8 T cells were isolated as described (section 2.11.1) and 8 x 106
T cells, diluted in 200µl sterile PBS, were intravenously injected into the lateral
tail vein of TF-OVA mice and TF-OVA×CD11cDTR mice, to induce hepatitis
or into iFABP-OVA mice to induce gut-activated T cells.
2.14.2 Depletion of dendritic cells
In order to deplete dendritic cells, 4 ng diphtheria toxin (DT) per gram body
weight was i.p. injected into TF-OVA×CD11cDTR mice. Control mice received
PBS. CD11cDTR mice (Jung et al., 2002) express the simian DTR (diphtheria
toxin receptor) fused to GFP (green fluorescent protein) under control of the
murine CD11c promotor. Application of DT leads to systemic depletion of
dendritic cells and can be followed by GFP expression, using flow cytomtry.
2.14.3 Depletion of macrophages by liposome-encapsulated clodronate
Liposome-encapsulated clodronate is used to deplete macrophages in rodents.
Phagocytosis of these liposomes leads to degradation of phospholipidbilayers
by lysosomal phospholipases, thereby releasing clodronate into the cytosol (van
Rooijen et al., 1997). Clodronate is misleadingly recognized as cellular pyrophos-
phate and synthesized to a non-hydrolizable ATP (adenosine triphosphate)
analog (Frith et al., 1997). The ATP analog inhibits the mitochondrial
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ATP/ADP translocase, thereby initiates mitochondrial pore openings and
release of molecular signals, which leads to cell death via apoptosis (Lehenkari
et al., 2002).
Multilamellar clodronate-liposomes were prepared as described earlier (van
Rooijen and Sanders, 1994) with minor modifications. A stock solution of
phosphatidylcholine (100mg/ml) and cholesterol (100mg/ml) in chloroform
was prepared. Subsequently a mixture of 860µl phosphatidylcholine and 80µl
cholesterol was transferred into a glass vial and evaporated by nitrogen gas. The
phospholipid-layer was dissolved in 10ml clodronate (2.5 g dichloromethylene-
bisphosphonate in ddH2O) by gently shaking at room temperature and sonicated
for five minutes till the solution became cloudy. After swelling the liposomes
at 4◦C, 1 h, they were centrifuged at 10,000 x g for 15 minutes. The clear lower
phase (clodronate) was collected and kept for the next preparation. The cloudy
upper phase (clodronate-encapsulated liposomes) was washed twice with sterile
PBS at 25,000 x g for 30 minutes and dissolved in 4ml PBS. Liposomes were
kept for no longer than 14 days. Control-liposomes were produced in the same
manner, but instead of adding clodronate sterile PBS was used. For systemic
depletion of macrophages in vivo, 100µl liposomes per mouse were injected
intravenously into TF-OVA mice.
2.14.4 In vivo migration assay
To analyze T-cell trafficking in vivo, migration assays using radioactively labeled
lymphocytes were performed (Siegmund and Hamann, 2006).
Naïve, liver-activated, and gut-activated OT-I CD8 T cells were isolated
as described (section 2.11.1, 2.12) and incubated for one hour at 37◦C in the
presence of 20 µCi/mL 51Cr (chromium) in complete RPMI. Following the
exclusion of dead cells by gradient centrifugation (Nycoprep 17%), cells were
washed, and 0.8 to 1 x 106 T cells were injected intravenously into wild-type,
TF-OVA, or iFABP-OVA mice. 20 hours after transfer, mice were sacrificed
and the following organs were taken: blood, peripheral, hepatic and mesenteric
lymph nodes, Peyer’s patches, small and large intestine, lung, liver, and spleen.
Radioactivity found within isolated tissue and the remaining body was measured
using a γ-counter.
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2.14.5 In vitro stimulation of T cells
To characterize cells for their potential to secrete cytokines, initially in vivo
activated T cells were re-isolated from the liver, spleen or mesenteric lymph
nodes and activated in vitro. T cells were cultured in complete RPMI at
37◦C and activated in the presence of 20 nM PMA (phorbol 12-myristate
13-acetate), which is an intracellular stimulator and 1µM ionomycin, which
functions as ionophor to transport PMA into the cell. After incubation for one
hour, brefeldin-A (5µg/ml) was added to inhibit the secretion of synthesized
cytokines. After an additional three hours, T cells were stained for surface
markers and intracellular cytokines and analyzed by flow cytomtry.
2.14.6 In vitro cytolysis assay
Liver-and gut-activated OT-I CD8 T cells were isolated as described (section
2.12) and analyzed for their ability to lyse target cells. 2 x 105 activated T cells
were incubated with 4 x 105 splenocytes, isolated from wild-type mice. One part
of splenocytes was previously labeled with 5µM CFSE (high) and pulsed with
1µg/ml SIINFEKL (as target cells), whereas the other part of splenocytes was
labeled with 0.5µM CFSE (low) and left untreated for 1 h. SIINFEKL-pulsed
splenocytes and control splenocytes were mixed in equal numbers and incubated
with liver-and gut-activated T cells for five hours. As control, splenocytes were
incubated without effector T cells. Target splenocytes were analyzed for CFSE
staining and specific lysis was calculated:
% specific lysis = 100× 1-(CFSE
low
control/CFSEhighcontrol)
(CFSElowtreated/CFSEhightreated)
2.15 ALT levels
The cytoplasmatic enzyme alanine aminotransferase (ALT) is mainly found
in hepatocytes. An increase in ALT indicates hepatic tissue damage. To
measure ALT in mice, blood was taken from the tail or submandibular vein,
and transferred into plasma-collection tubes.
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After centrifugation (6,000 x g, 10 min, RT) the supernatant (plasma) was
stored at -20◦C, until analyzed by a Roche Modular Analyzer. ALT is measured
in international units/liter (U/L).
2.16 Flow cytometry
The flow cytometer is a tool to detect and count single cells passing in a stream
through a laser beam. The detection of scattered light gives information about
the cell size (Forward Scatter) and the granularity (Side Scatter). Further
detection of the fluorescent emission of labeled antibodies is used to characterize
individual cells in a mixed population. Cells were analyzed on BD FACSCalibur
or FACSCanto II using the CellQuest and DIVA software.
Fluorescence-activated cell sorting (FACS) is a specialized form of flow
cytometry whereby cells of particular interest are detected by their fluorescent
labels and subsequently separated and sorted. Cells passing through a liquid
stream are separated into single cells per droplet. Based on their fluorescent
labels, cells pass an electrical charger. A subsequent opposite charge attracts
charged (positive or negative) cells and diverts them into tubes. Cells were
sorted on BDFACSAria I or II Sorter.
2.16.1 Analysis of surface proteins using flow cytometry
Analysis of cells due to their expression of specific proteins was performed using
fluorescently labeled antibodies. Cells were washed and dependent on experi-
ments, 0.1 to 1 x 106 cells were labeled with fluorochrome-coupled antibodies in
100 µl PBS/1%FCS for 20 minutes in the dark. Applied antibodies were used
according to manufacturer’s instructions or titrated before proceeding. When
biotinylated antibodies were used, cells were additionally stained with a sec-
ondary fluorochrome-coupled streptavidin antibody, for 20 minutes. Cells were
washed (500 x g, 4◦C, 5min), dissolved in 300µl PBS/1%FCS, and analyzed
by flow cytometry.
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2.16.2 Detection of intracellular proteins
After surface staining of cells, intracellular proteins may be labeled and ana-
lyzed. T cells were washed (500 x g, 4◦C, 5min), fixed and permeabilized using
IC-Fixationbuffer and permeabilization buffer according to manufacturer’s
instructions (eBioscience). For intracellular detection cells were stained with
GzmB- or IFN-γ-antibodies in permeabilization buffer (20min, RT). After
washing (500 x g, 4◦C, 5min) cells were analyzed by flow cytometry.
2.16.3 CFSE-staining
CFSE is a fluorescent dye used as cell tracker but also in proliferation assays,
due to an equal inheritance of the dye to daughter cells. CFDA-SE (carboxyflu-
orescein diacetate succinimidyl ester) is a non-fluorescent compound, which
passively diffuses into the cytoplasm of cells. When acetate groups are cleaved
by intracellular esterases, the fluorescent carboxyfluorescein succinimidyl ester
(CFSE) is generated, which remain intracellular. For in vivo proliferation assays,
tracking and re-isolation of T cells, 1 x 107 T cells were labeled with 15µM
CFSE (10min, 37◦C). The reaction was stopped by adding RPMI/5%FCS and
centrifugation (500 x g, 4◦C, 5min).
2.17 Molecular biology techniques
2.17.1 Screening of transgenic mice by PCR
Tail biopsies were digested in 200µl tail lysis buffer for one hour at 55◦C.
The reaction was stopped by incubating samples at 95◦C for five minutes and
diluted 1:5 with ddH2O. The PCR was prepared in a total volume of 25µl,
containing 1µl sample, Red Load Taq Master Mix, and 10µM primer (Tab. 3).
PCR protocol:
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Temperature Time
Initialization 94◦C 2 min
Denaturation 94◦C 30 sec
Annealing 55◦C (OVA) 62◦C (DTR) 30 sec 30 cycles
Elongation 72◦C 1 min
Final elongation 72◦C 10 min
Final hold 4◦C
PCR products were separated by 1.5% agarosis gel electrophoresis at 100V.
Pictures were taken from ethidium bromide-stained gels, visualized using UV
(ultraviolet) transillumination.
2.17.2 qRT-PCR
Liver tissue was mixed with Trizol and shredded with beads in a bench-
top homogenizer. After chloroform extraction, RNA was precipitated with
100%ethanol, diluted in ddH2O and RNA content was measured by a Nan-
oDrop spectrophotometer. After digestion of 10µg RNA with DNase I, cDNA
was synthesized from 2µg RNA using the SuperScript III First-Strand Syn-
thesis System, and real-time PCR was performed with the SsoFast EVAGreen
Supermix using an ABI Prism 7500 Sequence Detection System with primers
(Tab. 4). Ratios of mRNA levels were normalized to the housekeeping gene
Rpl4.
2.17.3 Microarray
Naïve, liver-activated, and gut-activated OT-I CD8 T cells were isolated as
described (section 2.11.1, 2.12) and used for transcriptome analysis. RNA-
Isolation, cDNA-synthesis, and in vitro transcription in biotinylated cRNA
were performed using the GeneChip 3’IVT Express Kit (Affymetrix). DNA was
removed by on-column digestion (Qiagen). The quality of RNA was determined
using the Agilent 2100 Bioanalyzer, and RNA content was checked with a Nano
Drop spectrophotometer. cDNA was synthesized from 300 ng RNA. cRNA was
synthesized using the Enzo RNA Transcript Labeling Kit (Affymetrix). 15µg
of fragmented biotinylated cRNA was hybridized to a mouse genome 430 2.0
GeneChip (Affymetrix) in two biological replicates for each of the three groups.
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Chips were washed and stained with streptavidin-phycoerythrin, and hybridized
microarrays were scanned with the GeneChip Scanner 3000, using the GCOS
(GeneChip Operating Software) software (both Affymetrix). Microarrays were
performed with the help of Dr. Andreas Grützkau and Heidi Schliemann.
2.17.4 Microarray analysis
All relevant GCOS data plus additional t tests were uploaded to the Bioretis
database (http://www.bioretis-analysis.de) and used for High Performance
Chip Data Analysis (HPCDA) to filter differentially expressed probe-sets with
the default query parameters (Menssen et al., 2009). The default parameters
use a signal threshold and the present call rate to detect the present genes and
a Bonferroni corrected Welch t test with the log 2 of fold changes (SLR; signal
log ratio) and/or the increase/decrease change call rate, calculated by GCOS
software with non-parametrical tests to obtain the significantly regulated genes.
These parameters were validated with the Affymetrix Latin Square dataset
(Menssen et al., 2009). High standard-deviations of some genes from the two
chips with liver-activated T cells were noted. Due to probable contamination
with RNA from liver tissue, genes were excluded using the following query
conditions:
Mean signal (liver chip 1&2)
SD < 2 AND
Mean signal (liver chip 1&2)
Mean signal (chip 3, 4, 5, 6) > 10 AND
signal of contaminated liver chip 2 > 200 AND
(signal liver chip 1 (x 3)) < (signal liver chip 2) OR
(signal liver chip 2–signal liver chip 1) > 1, 000
With this query, 67 probe sets were excluded from the list of HPCDA
significant genes. For hierarchical cluster analysis, Genes@Work (Lepre et al.,
2004) was used with gene vectors for normalization, along with Pearson w/mean
for similarity measure and center of mass as cluster type. For functional
annotations a subset of 2,537 differentially regulated IDs was uploaded to
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DAVID (Database for Annotation, Visualization and Integrated Discovery)
(Huang et al., 2009). The data analysis was performed with the help of Dr.
Joachim Grün.
2.18 Histological methods
2.18.1 Frozen histological sections
Perfused liver biopsies were frozen in liquid nitrogen, and stored at -80◦C.Liver
biopsies were embedded in Tissue-Tek and cut into 5µm frozen tissue sections
using a cryotome.
2.18.2 PFA-fixed histological sections
Perfused liver biopsies were fixed in 4%PFA for 24 hours and stored in 100%
EtOH. Liver biopsies were dehydrated in a Hypercenter Tissue Processor.
After paraffin-embedding, tissue was cut into 3µm sections using a microtome,
followed by deparaffinization and re-hydration using Roti-Histol and decreased
alcohol concentrations.
2.18.3 Hematoxylin and eosin staining (H&E)
Hematoxylin and eosin stains are used to recognize various tissue types and
morphologic changes in tissue. Liver tissue sections were incubated in haema-
toxylin that stains nuclei blue and eosin that colors the cytoplasm red. After
rinsing in water, sections were embedded in Kaiser’s glycerol gelatin.
2.18.4 Immunohistochemistry
PFA-fixed liver sections were incubated with unconjugated primary CD3, lami-
nin and F4/80 antibodies, followed by biotinylated secondary antibodies. After
incubation of streptavidin alkaline phosphatase, the target antigen is visualized
by an enzyme-substrate reaction with chromogen Fast Red. Nuclei were counter
stained with haematoxylin.
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2.18.5 Immunofluorescence
5µm sections of cryo-preserved liver tissue were incubated with monoclonal rat
antibodies against MAdCAM-1, ICAM-1, or VCAM-1, followed by incubation
with donkey anti-rat Alexa488-labeled or Alexa555-labeled antibody. Nuclei
were counter stained with DAPI. Negative controls were performed by omitting
the primary antibodies. Immunohistochemical staining was performed with the
help of Prof. Dr. Loddenkemper, Dr. Anja Kühl and, Simone Spieckermann.
2.18.6 Microscopy and analysis
Images were acquired using microscopes equipped with a camera and processed
with AxioVision software (Carl Zeiss, Jena, Germany). To calculate cells or
quantify the area percentage of immunohistochemical staining on liver sections,
ImageJ was used. Three visual fields of 0.6mm2 of each liver section were
converted into grayscale and split into red, green and blue channels. The
red-stained channel was used for thresholding and percentage of thresholded
area or particles were measured.
2.19 Statistical analysis
Statistical analysis was performed using GraphPad Prism software. The non-
parametric two-tailed Mann-Whitney U-test was used (*p<0.05; **p<0.01;
***p<0.001 were considered as significant). In the case of multiple comparisons
the Bonferonni-corrected Mann-Whitney U-test was used.
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3.1 Activation of CD8 T cells by antigen-presenting cells in
the liver of TF-OVA mice
TF-OVA mice express the antigen ovalbumin in hepatocytes and adoptive
transfer of antigen-specific naïve OT-I CD8 T cells induces hepatitis. Reconsti-
tution of TF-OVA mice with MHC class I-deficient bone marrow revealed that
professional APCs are incapable of presenting ovalbumin to naïve CD8 T cells.
Accordingly, cells not derived from bone marrow, such as hepatocytes and
LSECs, failed to induce effector T cells and indicating that professional APCs
are essential to induce effector CD8 T cells in the liver (Derkow et al., 2007).
Several professional and non-professional APCs, such as liver DCs, KCs, and
LSECs are capable of phagocytosis of cell debris from hepatocytes. These cells
ingest liver-derived ovalbumin, process it and cross-present it to naïve OT-I
CD8 T cells, leading to their proliferation in vitro (Derkow et al., 2011).
It remains to be determined, which professional APC in the liver is required
for efficient activation of naïve CD8 T cells in vivo. Therefore, experiments
that analyzed the role of KCs and hepatic DCs are described in the following
chapters.
3.1.1 TF-OVA×CD11cDTR mice as a model to study the influence of
dendritic cells in liver inflammation
TF-OVA mice were crossed to CD11cDTR mice (Jung et al., 2002) to analyze
the role of DCs during liver inflammation. CD11cDTR mice express the
primate DTR (diphtheria toxin receptor) fused to GFP (green fluorescent
protein) under control of the murine CD11c promotor. Intraperitoneal injection
of DT (diphtheria toxin) systemically depletes CD11c+GFP+DCs.
To estimate the extent and duration of DC depletion in the liver and spleen,
TF-OVA×CD11cDTR mice received a single injection of DT. Within 24 hours
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the administration of DT led to rapid depletion of CD11c+GFP+DCs in the
liver as well as in the spleen (Fig. 1A). The absence persisted for 48 hours,
after which liver and splenic DCs rejuvenated to original numbers (Fig. 1B).
Figure 1: Depletion of dendritic cells in the liver and spleen. TF-OVA×CD11cDTR mice
received a single injection of diphtheria toxin (DT). A) Spleen cells and CD11c-enriched liver cells
were stained with anti-CD11c antibody followed by flow cytometric analysis. Shown are dot plots
of GFP+CD11c+cells in the liver and spleen, 24 hours after DC depletion compared to untreated
control. B) Spleen and liver cells were isolated 24, 48, and 72 hours after DC depletion, counted
and stained with anti-CD11c antibody. Numbers of GFP+CD11c+DCs in the liver and spleen are
depicted. Each value at each time point represents an individual mouse.
In summary, TF-OVA×CD11cDTR mice provide a useful model to study
liver inflammation in the absence of DCs. However, as previously reported,
multiple injections of DT leads to the lethality of these mice (Jung et al., 2002;
Zaft et al., 2005). Therefore, DCs were depleted every two days and hepatitis
was analyzed for four days, in further experiments.
3.1.2 Dendritic cells are required for the activation of self-reactive
CD8 T cells in the liver
To analyze whether absence of DCs influences liver inflammation, OT-I CD8
T cells were transferred into TF-OVA×CD11cDTR mice to induce hepatitis.
Dendritic cells were depleted one day before and two days after T-cell transfer.
The absence of DCs ameliorated the hepatitis, indicated by reduced alanine
aminotransferases (ALT levels), an enzyme that is released into the serum when
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hepatocytes are destroyed. This reduction was not significant possibly due to
increased background ALT levels in mice that were DC-depleted only (Fig. 2A).
In addition, the absence of DCs led to decreased numbers of IFN-γ-producing
OT-I CD8 T cells in the liver and spleen compared with non-depleted mice
(Fig. 2B).
Figure 2: The absence of DCs ameliorates hepatitis. Transfer of naïve OT-I CD8 T cells into
TF-OVA×CD11cDTR mice induced hepatitis. Diphtheria toxin was injected i.p. one day before
and two days after the induction of hepatitis. The degree of liver inflammation and T-cell activation
was analyzed on day four. A) Dot Plot depicts ALT levels ± SD (alanin aminotransferase levels)
measured in serum from n≥7 mice in three separate experiments. ** p≤0.003, *** p≤0.0003,
ns=not significant; Bonferroni-corrected Mann-Whitney test. B) The number of interferon-γ
producing OT-I CD8 T cells in the liver and spleen were identified by ex vivo stimulation with
PMA/ionomycin. Two pooled experiments (n= 6, mean± SD) are shown. * p≤0.05, ** p≤0.01;
Mann-Whitney test.
In conclusion, the absence of DCs led to ameliorated hepatitis and reduced
effector function of OT-I CD8 T cells in the liver and spleen. That implies that
the liver-derived ovalbumin is cross-presented by hepatic and splenic dendritic
cells, which leads to efficient activation of naïve OT-I CD8 T cells, in early
stages of hepatitis.
3.1.3 Livers of DC-depleted mice display diminished infiltration of
T cells
Liver sections were analyzed to determine tissue damage and hepatic infiltration
of inflammatory cells in DC-depleted TF-OVA×CD11cDTR mice.
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Figure 3: Histological analysis of liver sections in TF-OVA×CD11cDTR mice. Experiments
were performed as described in figure 2). Liver sections were stained with H&E (haematoxylin
and eosin) (A, B, C). To identify T cells, immunohistochemical stainings with anti-CD3 were
performed (D, E, F). Representative images of six mice per group are shown (scale bar= 100µm,
magnification 100×). G) Box Plot depicts the number of CD3+T cells in liver sections quantified
by counting three visual fields (0.6mm2) of each liver section using the software ImageJ of n= 6
mice. * p≤0.025, ns=not significant; Bonferroni-corrected Mann-Whitney test.
The induction of hepatitis led to portal, periportal and lobular infiltration of
immune cells into the liver (Fig. 3B). Depletion of DCs led to decreased infil-
tration of immune cells (Fig. 3A) as compared with untreated mice (Fig. 3C).
To estimate T cells within the repertoire of immune cells in the liver, anti-CD3
staining was performed (Fig. 3D, E, F). Reduced numbers of CD3+T cells were
detected and quantified in DC-depleted mice suffering from hepatitis, compared
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with non-depleted mice (Fig. 3 G).
Thus, liver inflammation is diminished in the absence of dendritic cells,
characterized by reduced T-cell numbers.
3.1.4 Depletion of macrophages by clodronate liposomes
Clodronate encapsulated liposomes provide a tool to deplete macrophages in
mice. To determine the efficiency of macrophage depletion, TF-OVA mice
received a single injection of clodronate liposomes. Liver and spleen were
analyzed for the presence of CD11b+F4/80+macrophages for three consecutive
days.
Figure 4: Depletion of macrophages in the liver and spleen by administration of clo-
dronate liposomes. TF-OVA mice received a single intravenous injection of clodronate en-
capsulated liposomes. On day 1, 2, and 3, liver cells and spleen cells were isolated from
macrophage-depleted and untreated mice. Liver cells were additionally enriched by anti-CD11b
magnetic beads, as described in methods. Depicted are representative dot plots and percentage
of liver and spleen cells, positive for F4/80 and CD11b, analyzed by flow cytometry (n=2).
Figure 4 shows efficient depletion of CD11b+F4/80+macrophages in the liver
and spleen for two days, compared with the untreated control. After three days
macrophage-population recovered in the liver, whereas splenic macrophages
remained depleted.
In summary, the absence of Kupffer cells in the liver, after a single depletion,
lasted for two days. After that time, F4/80+ macrophages, evolving from a
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CD11b+cell population, repopulated the liver. Accordingly, in further experi-
ments, clodronate liposomes were administered every two days to ensure the
depletion of Kupffer cells.
3.1.5 The intensity of hepatitis is increased after Kupffer cell depletion
To study the effect of KC depletion on liver inflammation, naïve OT-I CD8
T cells were transferred into TF-OVA mice. In addition, macrophages were
depleted by clodronate liposome-injections every two days.
Figure 5: The intensity of hepatitis was increased in the absence of Kupffer cells. Hepatitis
was induced by transfer of naïve OT-I CD8 T cells into TF-OVA mice. Clodronate liposomes were
injected at day 0 and 3. A) Dot plot depicts ALT levels ±SD in the serum of mice determined
on day five. ** p≤0.005, ns=not significant; Bonferroni-corrected Mann-Whitney test. B)
The number of antigen-specific OT-I CD8 T cells in the liver and spleen were determined by
flow cytometry and cell count. C) The effector function of CD8 T cells in the liver and spleen
was measured by their ability to produce IFN-γ after in vitro stimulation with PMA/ionomycin.
Results are shown from two independent experiments (n=6, mean±SD). ** p≤0.01, ns=not
significant; Mann-Whitney test.
Within five days, the induction of hepatitis led to liver damage, as indicated
by increased serum ALT levels. The additional depletion of KCs increased
the severity of hepatitis, whereas the depletion of KCs alone did not alter the
ALT levels (Fig. 5A). Decreased numbers of antigen-specific OT-I CD8 T cells
were detected in the liver of KC-depleted mice. However, T-cell numbers in
the spleen remained similar (Fig. 5B). By measuring the pro-inflammatory
cytokine interferon-γ it was determined whether KC depletion influences the
generation of effector CD8 T cells. Independent of the presence of KCs, the
ability of OT-I CD8 T cells to produce this cytokine remained similar in liver
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and spleen (Fig. 5C).
Thus, Kupffer cell depletion led to more severe hepatitis, although less
antigen-specific CD8 T cells were recovered from liver. The data suggest that
Kupffer cells may play a role in priming tolerogenic T cells.
3.1.6 Kupffer cell-depleted mice display reduced numbers of
CD3+T cells in the liver
Hepatitis was induced in TF-OVA mice and Kupffer cells were depleted as
described (section 2.14.3). Liver sections were analyzed for the presence of
tissue damage, inflammatory cells, and Kupffer cells.
The induction of hepatitis led to similar portal, periportal, and lobular
infiltration of leukocytes into the liver, independent of the absence of KCs
(Fig. 6A, B). Infiltrating cells observed in the liver of KC-depleted mice did
not consist primarily of T cells. In fact, decreased CD3+T-cell infiltration was
observed in KC-depleted mice (Fig. 6D, J), as compared with control mice
(Fig. 6E, J). The absence of Kupffer cells in livers of clodronate liposome-
treated mice was confirmed by anti-F4/80 staining, a marker for macrophages
(Fig. 6G, I). No leukocyte infiltration or tissue damage has been observed in
livers of mice that were KC-depleted only, suggesting that clodronate liposomes
do not harm the liver (Fig. 6C, F, J).
In summary, the absence of Kupffer cells in mice suffering from hepatitis led
to reduced infiltration of CD3+T cells.
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Figure 6: Histological analysis of liver sections in Kupffer cell-depleted TF-OVA mice.
The experiment was performed as described in figure 5. A, B, C ) Livers sections were stained with
H&E (haematoxylin and eosin). D, E, F ) Immunohistochemical stainings with anti-CD3 antibody
were performed to indicate T cells or G, H, I) stainings with anti-F4/80 antibody to confirm the
absence of KCs. Depicted are representative images of six mice per group (scale bar= 100µm,
magnification 100×). J ) Box plot depicts the number of CD3+T cells quantified by counting
three visual fields (0.6mm2) per section of two independent experiments (n=6), using ImageJ.
* p≤0.025, ** p≤0.005; Bonferroni-corrected Mann-Whitney test.
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3.2 Migration patterns of liver-activated CD8 T cells
compared to naïve and gut-activated T cells
Naïve T cells circulate through blood and secondary lymphoid organs. Once
they encounter their specific antigen, they become activated and migrate into
tissues towards the site of inflammation. Gut-specific migration requires tissue-
specific adhesion molecules as well as appropriate receptors on the T-cell surface.
Little is known about T-cell migration into the liver, or the migration behavior
of T cells activated by liver-derived antigen. Therefore, in vivo migration-assays
with naïve, liver-activated, and gut-activated OT-I CD8 T cells were performed.
In the following sections the terms “liver-activated” and “gut-activated”
T cells are used. TF-OVA mice express the antigen ovalbumin in hepatocytes
(liver). OT-I CD8 T cells injected into TF-OVA mice were activated in the
liver and re-isolated from livers (liver-activated). iFABP-OVA mice express
the antigen ovalbumin in enterocytes of the small intestine and OT-I CD8
T-cell transfer leads to their activation in the GALT (gut-associated lymphoid
tissue). Gut-activated T cells were re-isolated from mesenteric lymph nodes of
iFABP-OVA mice.
3.2.1 Migration of naïve OT-I CD8 T cells in mice expressing ovalbumin
in the liver or in the small intestine
To analyze how the presence of the antigen ovalbumin influences the migration
of naïve T cells, radioactively labeled naïve OT-I CD8 T cells were transferred
into TF-OVA, iFABP-OVA, or wild-type mice. The amount of radioactivity
recovered from a specific organ correlates with the number of T cells found to
have migrated into this organ.
Naïve OT-I CD8 T cells migrated mainly to the secondary lymphoid organs in
wild-type mice. In contrast, the vast majority of OT-I CD8 T cells migrated into
the liver in TF-OVA mice in which the antigen was expressed in hepatocytes.
OT-I CD8 T cells transferred into iFABP-OVA mice displayed similar migration
patterns to the ones seen in wild-type mice and no preferential migration to the
site of antigen expression – neither in the small intestine nor in the associated
lymphoid structures – was observed (Fig. 7).
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Figure 7: Migration of naïve OT-I CD8 T cells in mice expressing ovalbumin in the liver
or in the small intestine. Naïve OT-I CD8 T cells were labeled with 51Chromium and injected
intravenously into wild-type, TF-OVA, and iFABP-OVA mice. Radioactivity was measured in
the indicated organs 20 hours after transfer (mLN, mesenteric lymph node; pLN, peripheral
lymph node). The percentage of recovered radioactivity is shown from three pooled experiments
(n≥ 5, mean± SD). * p≤0.016, ** p≤0.003; Bonferroni-corrected Mann-Whitney test. Note the
different scales for large and small organs.
Thus, presence of the antigen in the liver but not in the small intestine, leads
to accumulation of naïve OT-I CD8 T cells at the site of antigen presentation.
This suggests that the antigen is accessible to naïve T cells in the liver but not
in the gut.
3.2.2 Migration of liver-activated OT-I CD8 T cells compared to naïve
and gut-activated T cells in wild-type mice
It is known that T cells primed in the GALT preferentially migrate to the gut.
Whether T cells activated in the liver display organ-specific migration behavior
was analyzed in the following experiment: Liver-activated OT-I CD8 T cells
were transferred into wild-type mice. The influence of T-cell priming in the
liver on migration was compared to naïve and gut-activated OT-I CD8 T cells.
Naïve and liver-activated OT-I CD8 T cells mostly migrated to the secondary
lymphoid organs. In contrast, gut-activated OT-I CD8 T cells migrated to the
small intestine, and less recirculation to lymph nodes was observed. Activated
T cells accumulated in the livers of wild-type mice, irrespective of the site of
priming. Increased migration to the liver of gut-activated T cells compared to
liver-activated T cells was observed (Fig. 8).
In summary, OT-I CD8 T cells activated in the gut-associated lymphoid
tissues are licensed to migrate to the gut, while liver-activated OT-I CD8 T cells
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are not. In contrast, liver-activated CD8 T cells retain their ability to circulate
through the lymph nodes. Gut-activated CD8 T cells accumulated in the liver
to a larger extent than their liver-primed counterparts.
Figure 8: Migration of liver-activated OT-I CD8 T cells in wild-type mice, compared to
naïve and gut-activated T cells. Naïve, liver-activated or gut-activated OT-I CD8 T cells were
labeled with 51Chromium and transferred into wild-type mice. Radioactivity was measured in the
indicated organs 20 hours after transfer (mLN, mesenteric lymph node; pLN, peripheral lymph
node). The percentage of recovered radioactivity is shown from three pooled experiments (n≥ 5,
mean±SD). * p≤0.016, ** p≤0.003, ** p≤0.0003; Bonferroni-corrected Mann-Whitney test.
Note the different scales for large and small organs.
3.2.3 Migration of liver-activated OT-I CD8 T cells in mice expressing
ovalbumin in the liver or in the small intestine
The migration patterns of liver-activated T cells in the presence of ovalbumin
was investigated. Liver-activated OT-I CD8 T cells were transferred into
TF-OVA mice (antigen in hepatocytes), into iFABP-OVA mice (antigen in the
small intestine), and into wild-type mice to analyze whether the presence of
the antigen overrides the imprinted migration pattern.
Presence of the antigen in the liver led to preferential migration to the liver,
while migration to lymph nodes was slightly reduced (Fig. 9A). Liver-activated
OT-I CD8 T cells transferred into iFABP-OVA mice preferentially migrated to
the mesenteric lymph nodes but did not enter the small intestine (Fig. 9B).
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Figure 9: Migration of liver-activated OT-I CD8 T cells in mice expressing ovalbumin
in the liver or in the small intestine. Liver-activated OT-I CD8 T cells were labeled with
51Chromium and transferred into wild-type and TF-OVA mice (A) or into wild-type and iFABP-
OVA mice (B). Radioactivity was measured in the indicated organs 20 hours after transfer (mLN,
mesenteric lymph node; pLN, peripheral lymph node). The percentage of recovered radioactivity
is shown from three pooled experiments (n≥ 6, mean± SD). * p≤0.05, ** p≤0.01, ** p≤0.001;
Mann-Whitney test. Note the different scales for large and small organs.
Thus, OT-I CD8 T cells primed in the liver displayed preferential migration
towards the site of antigen expression while retaining their capacity to circulate
through lymph nodes. Although activated, they were incapable of gaining
access to the small intestine.
3.2.4 Migration of gut-activated OT-I CD8 T cells in mice expressing
ovalbumin in the liver or in the small intestine
Finally the migration patterns of gut-activated T cells were investigated. OT-I
CD8 T cells activated in the GALT were transferred into TF-OVA, iFABP-OVA,
or wild-type mice.
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Figure 10: Migration of gut-activated CD8 T cells in mice expressing ovalbumin in the
liver or in the small intestine. Gut-activated OT-I CD8 T cells were labeled with 51Chromium
and transferred into wild-type and TF-OVA mice (A) or into wild-type and iFABP-OVA mice (B).
Radioactivity was measured in the indicated organs 20 hours after transfer (mLN, mesenteric
lymph node; pLN, peripheral lymph node). The percentage of recovered radioactivity is shown
from three pooled experiments (n≥ 4, mean±SD). * p≤0.05, ** p≤0.01; Mann-Whitney test.
Note the different scales for large and small organs.
The majority of gut-activated OT-I CD8 T cells migrated to the liver. This
effect was enhanced by the presence of the antigen in the liver of TF-OVA
mice. In return, decreased accumulation of gut-activated OT-I CD8 T cells in
secondary lymphoid organs and in the small intestine was observed (Fig. 10A).
When the antigen was present in the small intestine of iFABP-OVA mice,
increased migration to the gut was observed (Fig. 10B).
Taken together, presence of the antigen in the liver or in the small intestine
promotes the migration of gut-activated OT-I CD8 T cells towards the site of
antigen expression. Further, gut-activated T cells accumulated in the livers of
mice, an effect that is amplified by the expression of ovalbumin in the liver of
TF-OVA mice. The gut-homing phenotype of gut-activated OT-I CD8 T cells
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was overridden by the presence of the antigen in the liver (as seen in Fig. 8).
In summary, specific migration patterns are imprinted in the gut and liver,
but these patterns are not stable. Licensing to the gut requires priming in
the gut-associated lymphoid tissue, and liver-activated OT-I CD8 T cells are
prohibited from entering the gut. Although activated, liver-primed CD8 T cells
retained the ability to migrate to lymph nodes. Migration to the liver increased
upon activation of CD8 T cells, and the fact that more gut-activated than
liver-activated CD8 T cells accumulate in the liver suggests different stages of
activation of these T-cell subsets.
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3.3 Phenotype of differentially activated OT-I CD8 T cells
The migration pattern of T cells and their access to specific tissues is regulated
through specific adhesion molecules and other molecules involved in trafficking.
Since activation of OT-I CD8 T cells in the liver or in the gut led to differential
migration patterns, the phenotype of these T cells was further characterized.
Transcriptome analysis and flow cytometry were used to study the molecules
that could be responsible for different migration patterns.
First, particular attention was paid to liver-activated CD8 T cells and their
expression of specific molecules, which may explain the capacity to migrate
through secondary lymphoid organs. Second, it was determined whether gut-
and liver-activated CD8 T cells express molecular patterns that enable their
migration into the opposite organ. Finally the degree of activation of liver-and
gut-activated OT-I CD8 T cells was analyzed.
3.3.1 Gene expression profile of naïve, liver-activated, and gut-activated
OT-I CD8 T cells
Based on the differential migration behavior of naïve, liver-activated, and gut-
activated OT-I CD8 T cells, transcriptome analysis was employed to study which
genes could be responsible for the different migration patterns. Gene expression
profiling of naïve and activated OT-I CD8 T cells identified 10,326 differentially
regulated IDs in total, as shown in figure 11A and (Appendix Fig. 20). Each
of the three circles represents one of three comparisons (7,543 IDs regulated
differentially between gut-activated and naïve, 8,045 IDs regulated differentially
between liver-activated and naïve and 3,226 IDs regulated differentially between
gut-activated and liver-activated).
For further analysis, three groups were selected (Fig. 11A):
• 1,081 IDs regulated differentially between all three groups
• 995 IDs regulated differentially between liver-activated and naïve T cells
as well as between liver-activated and gut-activated T cells
• 528 IDs regulated differentially between gut-activated and naïve as well
as between liver-activated and gut-activated T cells
This selection process resulted in a set of 2,604 differentially regulated IDs.
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In this dataset of 2,604 IDs, high standard deviations of some genes from
the two chips of liver-activated CD8 T cells were detected. Due to probable
contamination with RNA from liver tissue, IDs were excluded (as described in
methods, section 2.17.4), leaving a set of 2,537 IDs.
Hierarchical clustering of 2,537 IDs separated the samples into three main
groups, discriminating naïve, liver-, and gut-activated OT-I CD8 T cells, and
proved the homogeneity of biological replicates. The dendrogram shows that
the relationship between naïve T cells and gut-activated is closer than the
relationship between naïve and liver-activated T cells or between gut-and liver-
activated T cells (Fig. 11B).
Figure 11: Gene expression profile of OT-I CD8 T cells activated in liver or gut. Gene
expression profiling of purified naïve, liver-activated, and gut-activated OT-I CD8 T cells was
performed in duplicates. A) Three comparisons of gut-activated T cells versus naïve T cells,
liver-activated T cells versus naïve T cells and gut-activated T cells versus liver-activated T cells
are visualized in a Venn diagram. B) Hierarchical clustering was performed with 2537 IDs
containing the three groups, characterized in the Venn diagram, using Genes@Work.
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3.3.2 Function-related groups
Based on an interest in candidate genes responsible for specific immunological
processes and given a multitude of IDs, function-related gene groups were
generated with a set of 2,537 IDs.
Four function-related groups of interest were selected (Fig. 12A–D; Appendix
Tab. 5, 6, 7, 8):
• 144 IDs containing genes involved in migration, adhesion molecules, and
integrins
• 53 IDs containing genes involved in cytokines, chemokines and their
receptors
• 87 IDs containing genes involved in T-cell activation
• 122 IDs containing genes involved in apoptosis
Figure 12: Hierarchical cluster analysis of function-related groups. Four functional groups
were generated using the Database for Annotation, Visualization and Integrated Discovery
(DAVID). Heat maps generated using Genes@Work display four functional groups: (A) Adhesion,
migration and integrins, (B) Cytokines, chemokines and their receptors, (C) T-cell activation,
and (D) Apoptosis.
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The gene expression signature among naïve and differentially activated OT-I
CD8 T cells remained different when grouped in function-related groups and
restricted the number of candidate genes to a set of 406 IDs.
3.3.3 Selection of genes for protein analysis
An additional selection of specific IDs from these four function-related groups
was performed according to the following criteria: a known gene product,
availability of reagents to test for expression at protein level, and high probability
of the gene product to be related to the function assigned to the group.
Figure 13: Selection of genes for protein analysis. IDs from the four function-related clusters
were selected for further analysis at protein-level. Mean signals of specific genes are depicted,
calculated by pooling multiple IDs of the same genes.
Figure 13 shows mean signals calculated for selected genes. Expression of the
genes encoding granzyme B (Gzmb), the chemokine receptors CCR9, CXCR3,
and CXCR6, as well as integrin α4 (Itga4 ) were upregulated in gut-activated
T cells compared to liver-activated T cells and naïve OT-I CD8 T cells. In
comparison with gut-activated and naïve OT-I CD8 T cells, liver-activated
T cells displayed increased expression of the genes encoding Ly6C, integrins
αV (ItgaV ), α6 (Itga6 ), and β1(Itgb1 ), as well as PD-1, CD200, and Nrp-1.
Both liver-activated and naïve OT-I CD8 T cells showed increased expression
of Sell (encoding CD62L) compared to gut-activated T cells, while the genes
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encoding CCR9 and integrin β7 (Itgb7 ) were downregulated on liver-activated
compared to gut-activated and naïve CD8 T cells.
3.3.4 Liver-activated OT-I CD8 T cells express the integrins α4β1 and
α6β1
To validate selected genes at protein-level, flow cytometric analysis of naïve,
liver-activated and gut-activated OT-I CD8 T cells was performed.
Figure 14: Expression of integrins of differentially activated OT-I CD8 T cells. Naïve, liver-
activated, and gut-activated OT-I CD8 T cells were analyzed by flow cytometry regarding their
expression of integrins. A) Representative dot plots of integrin-expression, gated on CFSE+CD8+T
cells, are displayed. B) Results represent the percentages of integrin-expression of OT-I CD8 T
cells. C) Mean fluorescence intensity (MFI) was evaluated for α4β7. Results from at least two
independent experiments are shown (n≥ 6, mean± SD). * p≤0.016, ** p≤0.003, *** p≤0.0003,
ns=not significant; Bonferroni-corrected Mann-Whitney test.
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Increased expression of integrin β1 pairing with both α4 and α6 was observed
on liver-activated OT-I CD8 T cells. All three subsets of OT-I CD8 T cells
expressed the integrin αLβ2. Expression of integrin αVβ1 was negligible
(Fig. 14A,B). Although the same percentage of integrin α4β7 was detected on
gut- and liver-activated OT-I CD8 T cells, only gut-activated T cells displayed
increased intensity of this integrin (Fig. 14C).
3.3.5 Liver-activated OT-I CD8 T cells do not upregulate a specific
chemokine receptor
In line with the array-data (Fig. 13), the chemokine receptor CCR9 was detected
on gut-activated T cells but also on naïve OT-I CD8 T cells. In contrast, CCR9
was completely downregulated upon activation in the liver (Fig. 15A,B).
Figure 15: Expression of chemokine receptors on differentially activated OT-I CD8 T
cells. Naïve, liver-activated, and gut-activated OT-I CD8 T cells were analyzed by flow cytometry
regarding their expression of chemokine receptors. A) Representative histogram plots of chemokine
receptor-expression, gated on CFSE+CD8+T cells, are displayed. B) depicts the percentage of
T-cell subsets stained positive for chemokine receptors, and T cells stained positive for α4β7 and
CCR9 at the same time (C). At least two separate experiments are shown (n≥ 6, mean±SD).
* p≤0.016, ** p≤0.003, ns=not significant; Bonferroni-corrected Mann-Whitney test.
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Contrary to the gene array data, staining for CXCR3 was not different
between the three subsets of T cells, and CXCR6 was upregulated while CCR7
was downregulated on both types of activated T cells compared to naïve OT-I
CD8 T cells (Fig. 15A,B). Co-expression of α4β7 and CCR9 was restricted to
gut-activated CD8 T cells (Fig. 15C, Fig. 14A).
3.3.6 Liver-activated OT-I CD8 T cells display patterns of naïve and
activated T cells
As shown in Figure 16A and B liver-activated OT-I CD8 T cells upregulated
Nrp-1 compared to gut-activated and naïve T cells. Only gut-activated T cells
produced granzyme B (GZMB).
Figure 16: Expression of activation markers and inhibitory molecules. Naïve, liver-activated,
and gut-activated OT-I CD8 T cells were analyzed regarding their activation status by flow
cytometry. A) Representative histogram plots of activation markers and inhibitory molecules,
gated on CFSE+CD8+T cells, are displayed. B) depicts the percentage of T cells positive stained
for activation markers and inhibitory molecules. C) Box plot depicts the mean fluorescence
intensity (MFI) evaluated for CD62L. At least two independent experiments are shown (n≥ 6,
mean±SD). * p≤0.016, ** p≤0.003, ** p≤0.0003 ns=not significant; Bonferroni-corrected
Mann-Whitney test.
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Liver-activated and gut-activated T cells expressed CD25, CD44, CD200 and
PD-1 to a similar extent, while Ly6C-expression was reduced in gut-activated
OT-I CD8 T cells. The most striking difference was the expression of CD62L
on virtually all naïve and liver-activated OT-I CD8 T cells in contrast to
its down-regulation on gut-activated OT-I CD8 T cells (Fig. 16A,B). The
mean fluorescence intensity of CD62L was significantly higher in liver-activated
compared to naïve and gut-activated OT-I CD8 T cells (Fig. 16C).
3.3.7 Liver-activated and gut-activated OT-I CD8 T cells exhibit similar
effector function
Finally, it was determined whether activation in the liver or gut has an influence
on the effector function of CD8 T cells. Liver-and gut-activated OT-I CD8 T
cells were isolated and analyzed for their potential to produce the cytokine
interferon-γ and their potential to lyse target cells.
Figure 17: CD8 T cells activated in the liver and in the gut display similar effector
function. Liver-activated and gut-activated OT-I CD8 T cells were sorted for CFSE-staining and
analyzed in vitro for production of interferon-γ after stimulation with PMA/ionomycin (A) and
for cytolysis of target cells (B). Percentages of IFNγ+ T cells or specific lysis are shown from
three pooled experiments (n=3 , mean± SD).ns=not significant; Mann-Whitney test.
Liver- and gut-activated OT-I CD8 T cells produced similar amounts of the
pro-inflammatory cytokine interferon-γ after in vitro stimulation. They also
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displayed similar potential to lyse target cells, confirming that both subsets
of CD8 T cells have cytotoxic capabilities (Fig. 17).
Thus, T-cell activation in the liver and in the gut results in effector OT-I
CD8 T cells.
In summary, only gut-activated OT-I CD8 T cells express both markers
associated with homing to the gut, namely α4β7 and CCR9. In contrast, liver-
activated OT-I CD8 T cells express integrins α4β1 and α6β1, but CCR9 ex-
pression is lost upon priming in the liver. Both liver-activated and gut-activated
CD8 T cells display an activated phenotype and show effector function, but
liver-activated CD8 T cells retain markers of naïve cells, namely CD62L and
Ly6C.
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3.4 Expression of cell adhesion molecules in the inflamed
liver
3.4.1 RNA levels of cell adhesion molecules
Quantitative RT-PCR analysis of normal and inflamed liver tissue was per-
formed to determine whether inflammation leads to up-regulation of adhesion
molecules. Corresponding to the integrins specifically regulated on liver- and
gut-activated OT-I CD8 T cells, the following adhesion molecules were analyzed:
• ICAM-1 (intercellular adhesion molecule 1) a binding partner for αLβ2
• VCAM-1 (vascular cell adhesion molecule 1) a binding partner for α4β1
• MAdCAM-1 (mucosal addressin cell adhesion molecule 1) a binding
partner for α4β7
ICAM-1 and VCAM-1 were expressed constitutively in non-inflamed livers but
were strongly upregulated upon inflammation. In contrast, MAdCAM-1 was
not expressed in non-inflamed livers but reached detectable levels in inflamed
livers (Fig. 18A–C).
Figure 18: RNA levels of adhesion molecules in the inflamed liver. Hepatitis was induced
by transfer of naïve OT-I CD8 T cells into TF-OVA mice. On day five, mRNA levels of ICAM-1
(A), VCAM-1 (B), and MAdCAM-1 (C) were analyzed in liver tissue by qRT-PCR and normalized
to the housekeeping gene RPL4. Box plots depicted are from two independent experiments
(n=8). ** p≤0.01, *** p≤0.001; Mann-Whitney test.
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3.4.2 ICAM-1, VCAM-1 and laminin are upregulated in the inflamed
liver
To confirm the up-regulation of adhesion molecules at protein level, immuno-
histochemistry of normal and inflamed liver tissue was performed.
Figure 19: Adhesion molecules are upregulated in the inflamed liver. The experiment was
performed as described in figure 18. On day five, livers of TF-OVA mice were sectioned and
analyzed for expression of (A) ICAM-1, (B) VCAM-1, (C) MAdCAM-1 (magnification 200×), and
(D) laminin (scale bar= 100µm, magnification 100×) by immunohistochemistry. Representative
images of n=4 mice are shown. The insert in (C) shows a mesenteric the lymph node as
the positive control for MAdCAM-1 staining. E) Box plot depicts the percent area of staining
of laminin, quantified in three visual fields (0.6mm2) of each liver section (n=4).* p≤0.05;
Mann-Whitney test.
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ICAM-1, VCAM-1, and laminin were upregulated in inflamed livers, while
MAdCAM-1 was not detected at protein level (Fig. 19A–E).
In summary, the adhesion molecules ICAM-1, VCAM-1, and laminin are
upregulated in inflamed livers and may be responsible for the binding of
CD8 T cells, which express the corresponding integrins, when activated in the
liver.
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Autoimmune liver diseases are of unknown cause and pathogenesis. It is assumed
that autoreactive T cells destroy either the hepatocytes, leading to autoimmune
hepatitis (AIH) or the cholangiocytes, leading to primary sclerosing cholangitis
(PSC) and primary biliary cirrhosis (PBC). Untreated, these diseases lead to
life-threatening conditions. Although effective therapies exist, a subgruop of
patients do not respond to therapy or suffer from side effects due to long-term
treatment. In addition, to date there is no available therapy for patients
suffering from PSC and the only life-extending option is transplantation of the
liver.
Animal models are required to study the initial immunological processes
leading to autoimmune liver diseases. A mouse model, which reflects the
characteristics of T cell-mediated hepatitis, was established in our laboratory.
TF-OVA mice express the model antigen ovalbumin in hepatocytes and transfer
of naïve antigen-specific CD8 T cells induces liver inflammation (Derkow et al.,
2007).
Given the lack of knowledge about immunological processes leading to au-
toimmune liver diseases, this study investigated, which professional APCs are
capable of activating CD8 T cells that in turn lead to liver inflammation. It
is now generally accepted that CD8 T cells are activated within the liver,
but knowledge about the fate of such liver-primed CD8 T cells is limited. In
addition, it is assumed that extrahepatic activation of T cells, for example in
the gut may contribute to autoimmune processes in the liver. Therefore, the
present study compared the migratory behavior of liver-primed CD8 T cells
and gut-activated CD8 T cells, and investigated their phenotype.
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4.1 Hepatic APCs and their role in activating naïve CD8 T
cells
Experimental models, in which antigens are presented in the liver, have demon-
strated T-cell activation (Klein and Crispe, 2006; Derkow et al., 2007) or
induction of apoptosis and tolerance (Liu et al., 2001; Bowen et al., 2004).
Various hepatic APCs are capable of presenting antigens to naïve CD8 T cells
in vitro (Ebrahimkhani et al., 2011; Derkow et al., 2011). In addition, non-
professional APCs such as LSECs as well as hepatocytes induce tolerance or
deletion rather than immunity (Bertolino et al., 2001; Limmer et al., 2000).
The contribution of professional APCs to the priming self-reactive T cells in the
liver remains unclear. Therefore, the present study investigated the influence
of both DCs and KCs as professional APCs on CD8 T-cell activation and liver
inflammation in vivo.
A subset of hepatic DCs contributes to the activation of naïve CD8 T
cells, leading to liver inflammation
In order to investigate whether hepatic DCs contribute to the activation
of antigen-specific naïve CD8 T cells in the liver and thereby induce liver
inflammation, double transgenic CD11cDTRxTF-OVA mice were generated, in
which the induction of hepatitis and the in vivo depletion of DCs are possible.
Our results show that DC-depletion reduces the number of pro-inflammatory
antigen-specific CD8 T cells in the liver, indicating that priming of T cells
in the liver is dependent on DCs. This result is in accordance with a study
demonstrating that the depletion of a subset of CD11chighMHC-IIhighDCs
impaired the activation of CD8 T cells in the liver (Plitas et al., 2008). However,
Plitas et al. did not investigated whether hepatic DCs are capable of inducing
effector CD8 T cells that mediate liver damage. Our data therefore extend
these finding as they show that the absence of DCs ameliorates the hepatitis
as indicated by decreased alanine aminotransferase levels (ALT), an enzyme
that is released into the serum when hepatocytes are destroyed.
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Although the absence of DCs reduces the severity of hepatitis, liver damage
was not fully prevented. Unexpectedly, the depletion of DCs led to increased
ALT levels by itself. This effect may be explained by the limitations of the
CD11cDTR model, since multiple injections of diphtheria toxin are lethal (Jung
et al., 2002), possibly because the diphtheria toxin receptor is expressed on radio-
resistant non-hematopoietic cells (Zaft et al., 2005), and their depletion might
influence the immunological homeostasis in the liver.Alternatively, elevated
ALT levels results from a toxic effect on the liver.
Another possible reason why DC depletion did not fully prevents liver damage
is that various other APCs exist in the liver, which are capable of activating
CD8 T cells. Non-professional APCs such as LSECs as well as hepatocytes have
been shown to prime CD8 T cells in the liver, but they rather induce T-cell
tolerance and deletion instead of immunity (Limmer et al., 2000; Bertolino et al.,
1999). These findings are consistent with data from our group. Derkow et al.
demonstrated that hepatocytes and LSECs fail to induce effector CD8 T cells
in bone marrow chimeras of TF-OVA mice, indicating that professional APCs
such as DCs and KCs are essential to induce liver inflammation (Derkow
et al., 2007). The data obtained in the present study therefore extend these
findings and identify hepatic DCs as inducers of effector CD8 T cells and liver
inflammation. Since depletion of DCs is a systemic treatment, we can not
be certain whether DCs from other organs such as the spleen influence the
activation of CD8 T cells in the liver. Depletion of DCs and simultaneous
splenectomy could circumvent this question in an experimental setting.
DCs are professional APCs and are key activators of adaptive immunity
in the lymph nodes where T-cell activation takes place. In contrast, DCs
in non-lymphoid organs such as the liver are generally considered immature
and thought to maintain tolerance (O’Connell et al., 2000). But tolerance is
broken when diseases occur and it was shown that more immunogenic DCs are
present in chronic human liver disease (Kelly et al., 2013). This might have
consequences regarding autoimmune reactions in the liver. Autoantigens are
constantly expressed and presented by hepatocytes, usually leading to tolerance
and deletion of CD8 T cells (Bertolino et al., 2001; Wuensch et al., 2006), but
DCs may take up these antigens from hepatocytes (Leiriao et al., 2005) and
70
4 Discussion
induce immunity leading to activation of effector CD8 T cells and liver
inflammation under inflammatory conditions. An understanding of different
subsets of DCs during inflammation in the liver would be helpful to develop
therapeutics based on modulation of these cells as currently tested in patients
with type I diabetes (Giannoukakis et al., 2011).
In summary, our data indicate that a subtype of hepatic DCs cross-presents
hepatocyte-derived antigen and generates antigen-specific effector CD8 T cells,
thereby contributing to liver inflammation. However, other APCs in the liver
obviously also induce the activation of CD8 T cells. Therefore, the next section
addresses KCs as potential APCs.
Kupffer cells maintain tolerance in the liver
The above discussed experiments showed that hepatic DCs contribute to liver
inflammation. However, other professional APCs such as KCs reside within the
liver and were reported to be immunogenic (Schumann et al., 2000), whereas
other studies demonstrated their tolerogenic role (Breous et al., 2009; You
et al., 2008). Therefore, this study investigated whether KCs, the liver resident
macrophages, generate antigen-specific effector CD8 T cells and thereby con-
tribute to hepatitis in vivo. By injecting liposome-encapsulated clodronate into
TF-OVA mice macrophages are effectively depleted and liver inflammation can
be analyzed in the absence of KCs.
The present study demonstrates that ablation of KCs increases the severity
of T cell-mediated hepatitis. This result is in line with a report, in which KC
depletion in a mouse model of hepatitis B also leads to increased hepatitis
(Sitia et al., 2011). Yet, there are contradictory reports showing that KC
depletion resolves liver inflammation in Con A-induced hepatitis (Schumann
et al., 2000). Since Con A is binding to LSECs and KCs (Knolle et al., 1996),
thereby promoting the secretion of pro-inflammatory cytokines and T-cell
activation (Schumann et al., 2000), the outcome of KC depletion may differ in
the antigen-specific hepatitis model we used.
KC depletion enhances the severity of hepatitis in our study. It would
be expected that liver inflammation is caused by increased infiltration of
antigen-specific CD8 T cells into the liver, which induce hepatitis in TF-OVA
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mice. In contrast, our data show that less effector CD8 T cells infiltrate
the liver in the absence of KCs, whereas the numbers of CD8 T cells in
the spleen remain constant. One possible reason for this observation is that
besides CD8 T cells other cytotoxic cells enter the liver that contribute to liver
inflammation. As shown by Sitia et al. KC depletion inhibits the removal of dead
hepatocytes, which in turn secrete danger signals that mediate the recruitment
of pro-inflammatory neutrophils that are suggested to increase the hepatitis,
indicated by elevated ALT levels (Sitia et al., 2011). Histological and flow
cytometric analysis in our study support this explanation, because the majority
of infiltrating cells in the liver in the absence of KCs are not composed of
T cells and large numbers of CD11b-positive cells, a marker primarily expressed
by neutrophils and monocytes, enter the liver. Alternatively, other T cells
are absent that may suppress the hepatitis. Another explanation for reduced
CD8 T-cell numbers in the liver is that KC-depletion prevents the adhesion of
T cells in the liver. KCs constitutively express the adhesion molecules ICAM-1
and VCAM-1, which are upregulated upon inflammation (van Oosten et al.,
1995), and ICAM-1 and VCAM-1-dependent retention of naïve and activated
CD8 T cells in the liver is an important mechanism of T-cell retention (Bertolino
et al., 2005; Mehal et al., 1999).
However, the mechanism of tolerance-induction by KCs in the liver is still
unclear. KCs are known to be effective cytokine-producers. Upon activation
they secrete pro-inflammatory cytokines such as IL-18 and TNF-α (Okamura
et al., 1995; Roland et al., 1994) but also anti-inflammatory cytokines such
as IL-10 (Knolle et al., 1995). However, little is known about KCs and their
cytokine-secretion in autoimmune liver disease and further studies are required.
In summary, KCs reduce the severity of hepatitis in our model by an unknown
mechanism. They may promote adhesion and activation of naïve CD8 T cells
in the liver and they induce tolerance by mechanisms that need to be further
investigated.
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4.2 Differential migration patterns of liver- and
gut-activated CD8 T cells
Naïve T cells patrol the secondary lymphoid organs and alter their migratory
phenotype upon activation, enabling them to gain access to target tissues.
While migration patterns of gut-activated T cells have been well described,
little is known about migration of T cells activated in the liver. Naïve and
memory T cells frequently migrate through the healthy liver and activated
T cells are retained preferentially (Luettig et al., 1999; Mehal et al., 1999).
Activated T cells found in the liver may originate from other organs, as reported
for patients suffering from the chronic liver disease PSC, in which gut-derived
T cells are present in the liver (Grant et al., 2001). These gut-derived T cells
may induce immune-mediated liver injury when they cause bystander hepatitis
with elevated liver enzymes, as reported for influenza infection (Belz.1998)
or autoimmune rheumatic diseases (Abraham et al., 2004). Since many of
the mechanisms behind this interplay between gut and liver remain unknown,
the migratory pattern of naïve CD8 T cells as well as liver-activated and
gut-activated CD8 T cells primed by the same antigen in vivo was investigated.
Antigen in the liver is more accessible to naïve CD8 T cells than antigen
expressed in the gut
In order to determine how presence of the antigen influences the migration
of naïve antigen-specific CD8 T cells, adoptive transfer experiments were
performed using recipients that express the antigen ovalbumin in the liver
(TF-OVA mice) or in the small intestine (iFABP-OVA mice).
Our results show that naïve CD8 T cells migrate directly towards the antigen
expressed in the liver, whereas the antigen in the small intestine does not lead
to accumulation of CD8 T cells at the site of antigen presentation.
Direct migration of CD8 T cells into the liver suggests that antigen-recog-
nition in the liver draining lymph nodes and subsequent migration into the liver
is dispensable as shown by others and our group before (Bertolino et al., 2001;
Derkow et al., 2007). Consistent with previous data, CD8 T cells are activated
and retained within the liver (Bertolino et al., 2001; John and Crispe, 2004).
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Abundance of hepatic APCs, the slow blood flow, and the unique architecture
of the hepatic sinusoids, enable T cells to directly contact hepatocytes and to
access the liver (Selmi et al., 2007; MacPhee et al., 1995; Warren et al., 2006).
The present study shows that expression of the antigen in the small intestine
does not lead to accumulation of naïve CD8 T cells in the small intestine. The
iFABP mouse model selected for this study expresses the antigen ovalbumin in
the small intestine and transfer of antigen-specific CD8 T cells into these mice
led to recruitment and CD8 T-cell activation in the mesenteric lymph node
and subsequent migration to the small intestine (Vezys et al., 2000). Naïve
T cells have to be activated in the GALT and acquire a gut-tropic phenotype
before they enter the lamina propria of the small intestine (Johansson-Lindbom
et al., 2005; Stenstad et al., 2007). This explains why naïve CD8 T cells are not
recruited to the small intestine within twenty hours in the in vivo migration
assay employed here.
In summary, the antigen expression in the liver leads to the accumulation
of naïve CD8 T cells at this site, whereas the antigen expressed in the small
intestine is not recognized.
Liver-primed T cells exhibit a distinct migratory profile compared to
gut-primed T cells
Several aspects are of interest regarding the migration of T cells activated
in the liver and in the gut: Liver-primed T cells may exhibit tissue-tropic
migration patterns in the same way as gut-derived T cells do. They may also
migrate to other organs such as the gut. Conversely, T cells initially activated
in the GALT may migrate to the liver where they are retained because they are
activated. To test this hypothesis liver-activated and gut-activated CD8 T cells
were transferred into wild-type mice to study tissue-tropic T-cell migration
independent of antigen-expression.
Both types of activated CD8 T cells accumulated in the liver, with higher
numbers of gut-activated than liver-activated CD8 T cells, implicating that
accumulation in the liver relates to the activation status of CD8 T cells. It has
been reported that activated T cells change their migratory properties upon
74
4 Discussion
activation and preferentially accumulate in the liver (Hamann et al., 2000;
Luettig et al., 1999; Mehal et al., 1999).
Our data show that CD8 T cells primed in the gut have access to the small
intestine, whereas CD8 T cells activated in the liver and naïve CD8 T cells
do not. In agreement with earlier studies, activation by APCs in the GALT
induces the gut-homing phenotype required for gaining access to the small
intestine (Stenstad et al., 2007). Licensing to the small intestine requires the
presence of retinoic acid in dendritic cells during priming (Iwata et al., 2004).
Clearly, priming in the liver does not imprint this gut-homing phenotype on
CD8 T cells despite the fact that retinoic acid is present in hepatic stellate
cells. While in vitro experiments had suggested that none of the liver APCs
are suited to induce this gut-homing phenotype in CD8 T cells (Eksteen et al.,
2009), this finding was disputed by the in vitro finding that LSECs are capable
of imprinting the gut-homing phenotype on CD4 T cells (Neumann et al., 2012).
Our study demonstrates that CD8 T cells primed in the liver in vivo do not
migrate to the intestine despite the fact that professional and non-professional
APCs are present in sufficient quantity and are capable of presenting the antigen
(Derkow et al., 2011).
We also observed that CD8 T cells activated in the liver display a distinct
migratory profile. They preferentially migrate to liver and spleen, reflecting
their activated status. However, they retain the ability to migrate through
lymph nodes, whereas gut-primed CD8 T cells re-circulate through lymph
nodes less frequently. Previous reports have shown that accumulation of T cells
recognizing their antigen within the liver are retained and that the liver acts
as a “T-cell graveyard” or as a “killing field” for activated T cells (Mehal
et al., 2001; Bertolino et al., 2001; Crispe et al., 2000). The liver acting as
a “T cell graveyard” implies that activated T cells undergoing programmed
cell-death accumulate in the liver, whereas the “killing field” theory suggests
that activated T cells are trapped and actively deleted in the liver (Crispe
et al., 2000). Our data dispute these findings, since liver-activated CD8 T cells
accumulate in the liver, but a large proportion of these T cells are capable of
re-circulating through the lymph nodes. Regarding gut-primed CD8 T cells,
which accumulated in the liver to a larger extent, it could be hypothesized
that they exert bystander hepatitis upon deletion in the liver. The in vivo
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migration-assay employed in this study is not suitable to analyze whether
T cells that migrated into different organs are effector cells, undergo apoptosis
or become anergic and further studies are required.
In conclusion, CD8 T cells activated by gut-derived antigen express the
gut-homing phenotype and gain access to the small intestine. The activation
of CD8 T cells increases their migration to the liver, independent of the site
of activation. CD8 T cells activated in the liver exhibit a distinct migration
behavior in vivo. While they show no specific liver-tropism, they have the
potential to migrate into lymph nodes and are prohibited from entering the
gut.
Presence of antigen in the liver and gut enhances migration of activated
T cells to the respective sites
Based on findings on migration of liver- and gut-primed CD8 T cells in wild-type
mice, it was important to determine additional effects of antigen-expres-sion in
liver or gut on T-cell migration. CD8 T cells activated by gut-derived antigen
may migrate to the liver where they encounter their cognate antigen, inducing
autoimmunity. It may also re-direct liver-primed CD8 T cells into the gut.
Presence of the antigen in the liver led to more pronounced accumulation of
naïve as well as liver-and gut-activated CD8 T cells in the liver. In addition,
antigen-expression in the liver overrode the gut-tropism of gut-activated T cells,
which accumulated in the liver in larger numbers. Expression of the antigen in
the small intestine drove liver-derived CD8 T cells into the mesenteric lymph
node, but they did not gain access to the small intestine.
Studies have shown that skin- and gut-tropic T cells express alternative
homing receptors after re-stimulation with APCs of the reciprocal organ in
vitro and in vivo (Mora et al., 2005; Oyoshi et al., 2011). In our study, liver-
primed CD8 T cells displayed more pronounced migration into the mesenteric
lymph nodes when the antigen was expressed in the small intestine. Thus,
it is possible that they enter the small intestine at later time points after re-
programming of their adhesion molecules. Conversely, presence of the antigen
in the liver led to profound accumulation of gut-primed CD8 T cells in the liver
and overrode gut-tropic migration. Gut-activated T cells may enter the liver
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simply because they are activated, but recognizing their cognate antigen in the
liver may induce re-programming of their phenotype as well.
Gut-primed CD8 T cells that recognize their antigen in the liver, may induce
liver pathology in the context of inflammatory bowel disease, as proposed
for patient afflicted with PSC (Grant et al., 2001; Eksteen et al., 2004). A
possible explanation for their capability to migrate to the gut would be that
chronic gut-inflammation induces pro-inflammatory changes in the local hepatic
environment and improves the co-stimulatory capacity of APCs in the liver
as recently shown by our group (Seidel et al., 2013). It is also possible that
antigens originating from the inflamed intestine enter the liver (Terjung and
Spengler, 2009), thereby leading to cross-reaction with gut-derived T cells.
Together, this study indicates that antigen expression enhances migration
of activated CD8 T cells to the respective sites. Gut-activated CD8 T cells
are re-directed to the liver and may cross-react with their cognate antigen. In
contrast, liver-primed CD8 T cells have no access to the small intestine, even
when the antigen is expressed there.
4.3 Comparison of the phenotype of CD8 T cells activated
in the liver or in the gut
Based on the observed distinct migration patterns of liver- and gut-activated
CD8 T cells, the question arises whether different homing receptors or different
activation-patterns are induced. The phenotype of naïve, liver-activated, and
gut-activated CD8 T cells was characterized by transcriptome analysis. The
number of differentially regulated genes between the three CD8 T-cell popula-
tions was surprisingly high. Therefore, genes were selected that were relevant
for the migratory behavior and the activation-status of CD8 T cells and were
further analyzed at protein level.
Adhesion molecules on liver-activated and gut-activated CD8 T cells
As previously discussed, naïve CD8 T cells transferred to TF-OVA mice migrate
to the lymph nodes, but also accumulate in the liver. Little is known about
molecules that are responsible for the migration and adhesion of T cells to the
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liver and no liver-specific adhesion molecule was reported so far.
The present study shows that liver-activated CD8 T cells upregulate the
integrin β1, which is co-expressed with integrins α4 and α6, thereby forming
ligands for laminin and VCAM-1. Integrins αL and β2, which dimerize to form
a ligand for ICAM-1, are expressed on naïve, liver-activated, and gut-activated
CD8 T cells. Apart from integrins on T cells, we also analyzed their ligands in
liver tissue. ICAM-1 and VCAM-1 as well as laminin are expressed constitu-
tively in non-inflamed livers, but are strongly upregulated upon inflammation,
suggesting that these molecules promote adhesion of CD8 T cells in the liver.
These results are consistent with previous reports showing that liver-primed
CD8 T cells upregulate the integrins α4 and αL, and blocking of VCAM-1 and
ICAM-1 reduces the adhesion of CD8 T cells to the liver (John and Crispe, 2004;
Bertolino et al., 2005). Whereas there is evidence that laminin is expressed
in the inflamed liver (Couvelard et al., 1993; Xu et al., 2003), upregulation
of integrin α6β1 on liver-activated CD8 T cells has not been reported so far,
suggesting a further mechanism for T-cell adhesion discovered in our model.
While the chemokine receptors CXCR3, CXCR6, and CCR5 are expressed on
T cells infiltrating the inflamed liver (Curbishley et al., 2005; Boisvert et al.,
2003; Murai et al., 1999), we found no specific chemokine receptor upregulated
on liver-primed CD8 T cells.
We also observed that gut-activated CD8 T cells migrate to the small
intestine, whereas liver-activated and naïve CD8 T cells do not. As expected,
the gut-homing markers α4β7 and CCR9 were co-expressed on gut-activated
CD8 T cells only. In contrast, liver-activated CD8 T cells also expressed α4β7,
but CCR9 was completely downregulated. In addition, CCR9 is constitutively
expressed on naïve CD8 T cells in mice (Carramolino et al., 2001), but they
do not express α4β7. These data suggest that only the co-expression of both
molecules enable CD8 T cells to enter the small intestine, although CCR9-
independent migration to the small intestine was reported in another model
(Stenstad et al., 2007).
Finally, the present data demonstrate that CD8 T cells activated in the gut
show a strong tendency to migrate to the liver, an effect that is amplified in the
presence of their nominal antigen in hepatocytes. In livers of patients suffering
from PSC gut-derived T cells and mucosal addressins are detected (Grant
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et al., 2001; Eksteen et al., 2009). In the model studied here, gut-activated
CD8 T cells express the integrin α4β7, but also αLβ2 and low amounts of
α4β1. In contrast to ICAM-1 and VCAM-1, the binding partner for αLβ2 and
α4β1, both expressed in the liver, MAdCAM-1, the binding partner for α4β7,
was not detected in the inflamed liver by immunofluorescence although a weak
signal was observed at mRNA level. The migration behavior of gut-activated
T cells to the liver is likely explained by their activated phenotype per se (Mehal
et al., 1999; Hamann et al., 2000) and our data also suggest that interaction
of CD8 T cells with ICAM-1 and VCAM-1 may enhance accumulation of
gut-primed CD8 T cells in the liver.
In summary, specific integrins are upregulated on liver-primed CD8 T cells,
but no chemokine receptor was specifically induced in the liver. Based on these
findings, we propose that retention of CD8 T cells in the liver is accomplished
through interaction of αLβ2 with ICAM-1, α4β1 with VCAM-1, and adher-
ence of α6β1-positive CD8 T cells to laminin. Further studies are required
to elucidate whether integrin β1 – in particular when pairing with integrin
α6 – mediates T-cell adhesion in the sinusoids. Adhesion of gut-activated
CD8 T cells in the liver is mediated by ICAM-1 and VCAM-1, but it remains
to be investigated whether there is an additional effect of the gut-homing
markers α4β7 and CCR9 on migration to the liver, as proposed for patients
with PSC.
Liver-primed CD8 T cells display a hybrid phenotype that mediates
migration to multiple sites
We hypothesized that priming of CD8 T cells in the liver results in a distinct
phenotype and analyzed various molecules on liver-primed T cells with the aim
of identifying markers that distinguish them from CD8 T cells activated in
other organs.
Besides the profound differences regarding expression of integrins, strik-
ing differences regarding activation markers were noted. While gut-primed
CD8 T cells showed the typical hallmarks of activated T cells, liver-primed
CD8 T cells displayed a hybrid phenotype. They expressed CD44, reflecting
their activated status but also CD62L, resembling naïve cells, as well as Ly6C,
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previously reported on memory T cells (Cerwenka et al., 1998). CD62L is ex-
pressed by the majority of naïve T cells and specific subsets of memory T cells
and mediates homing to peripheral lymphoid organs (Arbones et al., 1994;
Sallusto et al., 1999). Ly6C expression on CD8 T cells differentiates central
from effector memory cells, supports homing to lymph nodes, and potentiates
adhesion of CD8 T cells to ICAM-1 (Hänninen et al., 2011). Liver-activated
CD8 T cells expressed high levels of CD44, CD62L, and Ly6C, resembling
central memory cells, confirming recent data from CD8 T cells primed on
LSECs (Böttcher et al., 2013). Expression of these molecules therefore explains
two of the characteristics of liver-activated CD8 T cells in our model, namely
circulation through lymph nodes and accumulation in the liver.
It can be argued that the distinct phenotype of liver-primed CD8 T cells re-
sults from incomplete activation in the liver.While this possibility can not be ex-
cluded, our analysis regarding the effector function of liver-primed CD8 T cells
revealed their potential to produce pro-inflammatory cytokines and to lyse tar-
get cells. In contrast to gut-primed CD8 T cells, liver-activated CD8 T cells did
not produce granzyme B and they may use the alternative Fas/FasL-pathway
to destroy target cells (Roth and Harch.2004).
Apart from the expression of the more common markers, we detected an
unusual molecule, namely Nrp-1 (Neuropilin-1), which is highly upregulated
on liver-primed CD8 T cells compared to gut-activated CD8 T cells. Nrp-1,
formerly known as a neuronal receptor (Kolodkin et al., 1997), is expressed
on CD4 Tregs, conventional CD4 T cells, and CD8 T cells (Bruder et al., 2004;
Yadav et al., 2012; Milpied et al., 2009). It is essential for initiation of the
primary immune response (Tordjman et al., 2002) and promotes prolonged
contact of CD4 Tregs with immature DCs (Sarris et al., 2008). Recently it
was reported that Nrp-1 is expressed on CD8 T cells activated by LSECs in
a bone marrow chimeric mouse model (Böttcher et al., 2013). In contrast to
this model, in which CD8 T cells are exclusively primed by LSECs, CD8 T-cell
activation is mediated by professional and non-professional APCs in our model
(Derkow et al., 2007). Our data suggest that Nrp-1-positive CD8 T cells are
not exclusively induced by LSEC and not restricted to T cells lacking effector
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function. It requires further investigation whether expression of Nrp-1 on
liver-primed CD8 T cells regulates their activation status or promotes adhesion
within the liver. Finally, the analysis of specific markers on T cells and their
ligands found in this study should be extended to human T cells and livers of
patients suffering from autoimmune liver diseases.
In summary, we characterized the population of CD8 T cells generated by
priming in the liver, which shows both distinct activation status and migratory
behavior in vivo. We demonstrate that CD8 T cells activated in the liver
exhibit effector function. While accumulating in the liver they also retain their
ability to circulate through lymph nodes, explained by a hybrid phenotype,
with aspects of naïve, effector, and also central memory CD8 T cells.
4.4 Conclusion
The present study provides evidence that hepatic DCs are effective APCs,
which induce functional effector CD8 T cells in the liver and contribute to liver
inflammation in our mouse model. In contrast, KCs ameliorate inflammation
in the liver. Thus, whereas hepatocytes, LSECs, and KCs play a tolerogenic
role, hepatic DCs may contribute to the pathogenesis of T cell-mediated liver
diseases.
T-cell priming in the liver in vivo induces effector CD8 T cells that have a
distinct phenotype and differ from that of CD8 T cells primed in the gut. Liver-
primed CD8 T cells express an unusual molecule, namely Nrp-1 and the integrins
αLβ2, α4β1, and α6β1. The corresponding ligands ICAM-1, VCAM-1, and
laminin are upregulated in the inflamed liver, suggesting that adhesion of
T cells in the liver is accomplished through these molecules. Therefore, these
interactions are a possible target for blocking and may provide an opportunity
to inhibit T cell-mediated pathology in the liver.
Activation of CD8 T cells in the liver also induces a specific migration
behavior. Liver-primed CD8 T cells accumulate in the liver, but also migrate
to lymph nodes, explained by their hybrid phenotype, which reflects aspects of
naïve, effector, but also central memory CD8 T cells. They may interact with
APCs and other immune cells in the lymph nodes, possibly influencing immune
homeostasis.
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Whereas liver-activated CD8 T cells have no access to the gut, gut-primed
CD8 T cells migrate into the small intestine, depending on the regulation of gut-
specific homing molecules. In addition, gut-primed CD8 T cells preferentially
accumulate in the liver, an effect that is amplified in the presence of their
nominal antigen in hepatocytes. Thus, migration of activated CD8 T cells is
leading from the gut to the liver, but not from the liver to the gut. Therefore,
it is possible that extrahepatic activation of CD8 T cells contributes to the
development of liver pathology. But it is unlikely that CD8 T cells primed in
the liver directly influence the mucosal immune system.
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Supplementary data
Figure 20: Gene expression profile of 10,326 IDs, differentially regulated between naïve,
liver-activated, and gut-activated CD8 T cells. Gene expression profiling of purified OT-I
CD8 T cells was performed in duplicates. Hierarchical clustering was performed with 10,326 IDs
containing the three groups of CD8 T-cell subtypes using Genes@Work.
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Table 5: Genes involved in adhesion, migration and integrins. The function related
group of 144 IDs was generated using the Database for Annotation, Visualization and
Integrated Discovery (DAVID) and used for Figure 12A.
Affy Number Gene Symbol gut-activated liver-activated naive
1415821_at Nptn 2262.8 2154.8 1757.4 1519.6 1343.3 1321.3
1416034_at Cd24a 51 132.8 236.2 434.7 920.8 189.1
1416271_at Perp 76.7 55.1 111.4 106.7 0.6 2.6
1417122_at Vav3 110.9 166.4 177 184.6 59.6 59.6
1417171_at Itk 965 876.4 606.1 643.8 1636.4 1845.1
1417391_a_at Il16 1187.8 1061.8 920.6 923 1346.9 1436.1
1417523_at Plek 186.1 137.6 271.5 230.1 17.4 3.6
1417756_a_at Lsp1 3143.8 2704.3 2732.9 2006.8 1846.7 2199.8
1417976_at Ada 186.7 157.7 62.9 51.8 126.5 115.6
1418014_a_at B4galt1 750 718.8 487.5 358.8 906.1 918.4
1418084_at Nrp1 166.5 313.1 1016.4 778 28.2 27.5
1418126_at Ccl5 404.9 310.2 191.5 64.1 2536.9 1695.7
1418230_a_at Lims1 989.2 696.6 1281.9 1205.3 621.5 630
1418340_at Fcer1g 34 94 322.9 151.6 130.5 68.7
1418465_at Ncf4 379.3 272 256.6 182 458.9 487.1
1418741_at Itgb7 1940.7 1694.6 1191.8 955 1549.4 1816.4
1418770_at Cd2 1855.7 1605.3 916 494.7 2515.1 2588.7
1418831_at Pkp3 579.4 548 438 317.1 264.9 321
1418925_at Celsr1 124.4 136.7 92.5 60.2 198.1 208.2
1419128_at Itgax 153.2 79.6 33.1 23.1 46.4 20.3
1419226_at Cd96 1276.3 1139 599.9 495.1 968.7 1013.7
1419394_s_at S100a8 29.1 195.2 1563.9 697.4 2084.1 654.5
1419412_at Xcl1 1121.1 1476.8 1883.9 2299.2 33.9 60.9
1419480_at Sell 1149.6 1477.3 5108.3 4362.2 4555 4635.4
1419481_at Sell 1442.9 1647 5508.9 5000.9 4898.3 4684.4
1419561_at Ccl3 95.4 127.6 189.7 149.1 10.9 8.9
1419768_at Cd22 121.9 248.4 73.2 48.8 173.6 56.2
1420699_at Clec7a 22.4 70.8 170.8 79.4 41.2 28.1
1420996_at Plxna3 23.2 38.7 64 76.2 30.1 34.4
1421194_at Itga4 245.9 285.1 158.1 140.8 94.7 71.5
1421420_at Ccr10 25.4 8.8 90.4 77.2 24.4 5.4
1421614_at Zan 1.9 2.9 52.3 70.7 1 1.7
1421861_at Clstn1 93.2 82.8 60.6 62.1 103.2 108.3
1421919_a_at Ccr9 708.7 629 6.6 0.6 323.1 351.3
1421920_a_at Ccr9 1933 1641.8 12.8 3.9 1022.6 1259.6
1421926_at Mapk11 68.7 88.2 142.5 167.2 44 79.7
1422445_at Itga6 595.3 700.3 1052.2 852.8 487.9 551.3
1422818_at Nedd9 578.8 596.5 481.5 416.6 854 909.3
1422875_at Cd84 432.2 519.5 659.5 517.5 370.6 422.2
1422938_at Bcl2 71.4 63.6 127.6 133.7 150.4 149.4
1422992_s_at Pik3cd 408.5 407.9 203.7 136.3 528.5 418.7
1423135_at Thy1 3698.3 3396.8 1904.7 1698.3 2777.1 3446.3
1423325_at Pnn 81.1 48.5 123.6 99.6 40.1 26.1
1423584_at Igfbp7 13.7 18 240.4 236.2 15 14.8
1423885_at Lamc1 53.2 40.5 21.2 16.7 20.1 14
1424027_at Pxn 194.7 190 114.8 117 172.7 234.5
1424067_at Icam1 278.8 257.6 167 120.6 674.6 807.1
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...Table 5 continued I
Affy Number Gene Symbol gut-activated liver-activated naive
1424139_at Rap1a 4288.8 4763.3 5749.8 5293.2 3633.2 4226
1424485_at Angptl3 1.2 1.2 18.1 58.3 0.5 0.7
1425515_at Pik3r1 136.6 158.5 117.5 92.7 289.8 221.3
1425518_at Rapgef4 74.3 81.7 45.1 24.1 368.1 389
1426300_at Alcam 253.6 274.6 519.8 497.8 34.8 15.7
1426301_at Alcam 186.7 209.2 349.5 386.3 24.4 10.3
1426794_at Ptprs 224.5 202.7 490.2 566.3 134.1 90.5
1426918_at Itgb1 200.5 187.3 635.8 261 128.2 100.7
1427064_a_at Scrib 124.5 143.7 190.6 213.6 156.1 160.7
1427419_x_at Ccr9 5297.2 4627.2 10.7 15.5 3535.2 3956.3
1427442_a_at App 15 70.9 121.8 45.3 242.6 180.5
1427615_at Itga4 19.4 23.7 43.3 75.4 4 5.7
1428471_at Sorbs1 157.3 190 267.2 272.7 208.3 203.6
1428585_at Actn1 1975.8 1969.3 972.6 630.3 3237 3854.5
1428850_x_at Cd99 437.3 374.7 529.1 553 115 140
1429882_at 6820431F20Rik 141 130.2 204.3 262.7 274 269.4
1430514_a_at Cd99 229.6 210.5 287 282.5 75 57.8
1431355_s_at Trpm7 65.5 53.9 117.8 164.4 98.3 81.6
1433963_a_at Fermt3 679.9 747.1 502.9 525.5 810.9 907.2
1434674_at Lyst 207.6 291.4 399.3 378.1 789 839.9
1434980_at Pik3r5 339.5 239.8 243.3 141.5 576.2 605.8
1435149_at Plcg1 1014.4 951.9 733.3 717.8 825.4 918.8
1435349_at Nrp2 60.8 64 20.7 23.2 87.9 90.7
1435448_at Bcl2l11 1326.7 1380.8 1052.9 792.7 628.6 590.2
1435518_at Rap1b 3700.3 3397.5 2945.9 2497.4 4032.7 3542.9
1435519_at Rap1b 5486.4 6358.5 4905.5 4514.1 7074 7107
1435807_at Cdc42 166.6 166.1 204.6 169.8 118.5 104.2
1436037_at Itga4 1613 1506.7 1334.5 994 888.9 785.8
1436173_at Dlc1 9 1.3 46.8 59.2 0.5 3.5
1436398_at — 129.5 97.7 171.7 293 267.9 280.7
1436740_at LOC100041567 217.2 237 299.3 387.4 460.4 414
1436778_at Cybb 46.4 163.1 214.1 92.1 225.9 95.7
1437122_at Bcl2 124.7 133.2 175.9 261.3 427.7 476.4
1437132_x_at Nedd9 696.6 748.7 413.3 509.5 1164.7 1516.9
1437466_at Alcam 71.5 80.4 217.4 194.5 11.4 4.9
1437467_at Alcam 174.6 176 352.3 383.2 10.8 11.9
1437502_x_at Cd24a 41 108 216.4 305.2 1033.4 366.9
1437717_x_at LOC100041567 343.6 315.6 458.1 570.5 679.3 633.2
1438279_at Dpp4 76.7 72.7 126.9 157.7 176.5 131.5
1438682_at Pik3r1 668.9 698.4 514.7 426.3 1396.3 1426.1
1440708_at Myh9 81.9 53 100.5 140.5 63.1 56.7
1440760_at — 19.2 34.2 32.4 51.3 97.8 119.2
1440770_at Bcl2 81.8 68.3 131 225.1 166.8 157.5
1441411_at Lims1 66.1 55.7 107.3 101.3 60.4 45.5
1443086_at Alcam 31.3 21.9 85.3 79.1 6.5 1
1443837_x_at Bcl2 76.2 59 138.4 176 131.6 156.3
1445395_at — 17.7 3.5 44.9 88.3 22.7 9.7
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Affy Number Gene Symbol gut-activated liver-activated naive
1446720_at Alcam 22.4 19.2 46.7 73.6 7.2 12.4
1447541_s_at Itgae 1282.2 648.3 14.9 9.2 1483 1807.7
1448123_s_at Tgfbi 14.4 58.5 195.7 58.4 79.8 40.7
1448182_a_at Cd24a 128.8 292.5 585 889.7 2182.7 607.2
1448234_at Dnajb6 2233.3 2416.8 1901.6 1752.9 1766 1638.4
1448327_at Actn2 163.6 112.3 24.3 31.7 478.3 555.5
1448371_at Mylpf 151.8 114.1 176.5 193.7 89.7 89.6
1448380_at Lgals3bp 849.7 786.5 215 127 973 1027.1
1448600_s_at Vav3 92.4 128.2 239.3 191.1 62.4 72.6
1448620_at Fcgr3 26.7 63.6 138.4 50.2 41.9 15.1
1448710_at Cxcr4 204.4 324.6 499.5 638.1 606.7 538.3
1448749_at Plek 498.7 466.7 735 611.2 51.6 23.5
1448756_at S100a9 23.3 87.1 1098.7 551 1290.8 412.5
1448943_at Nrp1 294.6 498.1 1731 1444.3 75.3 79.9
1448944_at Nrp1 114.2 244.7 729.4 549.9 7.4 17.7
1448996_at Rom1 187.2 204.3 105.8 52 97.7 100.4
1449127_at Selplg 2595.8 2823 1819.1 1344.9 2771.8 3217.4
1449156_at Ly9 736.7 765.7 589.8 602.4 765.1 811.4
1449216_at Itgae 454.4 227.3 10.1 11.2 452 538.6
1449399_a_at Il1b 29 65.2 181.4 148.8 49.9 37.7
1449507_a_at Cd47 3456.9 3426 2879.5 2135.2 2750.6 2305.6
1449846_at Ear2 /// Ear3 1.8 13.2 114.2 63.2 43.4 22
1450029_s_at Itga9 1 19.4 58.4 76.1 5.8 9.5
1450850_at Ezr 3064.5 3058.6 2582.2 2214 3287.3 3724.3
1450945_at Prkca 148.7 142.9 226.2 282.7 47.9 34.8
1451225_at Ptpn11 673.8 863.4 1255.4 1240.9 574.6 608.4
1451767_at Ncf1 160 211.1 28.1 7.5 124.2 83.3
1451910_a_at Cd6 977 773.6 572.9 537.5 946.4 1169.5
1452209_at Pkp4 705.9 709.8 548.9 577.9 1040.7 1163.7
1452545_a_at Itgb1 248.2 211 529.1 280.8 120.8 83.3
1452784_at Itgav 360.5 385.8 685.1 766.8 502.9 583.9
1452997_at 6820431F20Rik 722.6 591.5 745 889.4 670.1 585.1
1453016_at 2900042B11Rik 341.2 345.5 235 235 459.2 555
1453281_at Pik3cd 1411.5 1273.7 734.8 649.6 1694.2 1922.9
1453788_at — 91.5 179.1 282.9 302.6 50.8 93.9
1454268_a_at Cyba 3274.5 3029.1 2121.9 1743.9 2345.5 2567.1
1455257_at Itgb3 132.4 180.2 56.6 66.9 127.9 129.2
1455349_at LOC100048397 1148.6 1192.2 932.6 798.3 1444.8 1491.4
1456005_a_at Bcl2l11 2585.5 2669.2 2133.7 1591.6 1110.3 1018.9
1456135_s_at Pxn 1076.5 976.1 852.8 740.7 1158.2 1278
1456250_x_at Tgfbi 7.6 45.8 217.8 70.3 74.4 36.6
1456498_at Itga4 597.5 265 469.7 167.5 468.3 173
1456772_at Ncf1 498.7 635.8 145 52.1 399.8 340
1457120_at Itk 192.4 155.5 65.4 91.8 217.4 285.9
1457198_at Nrp1 42.5 54.3 218.9 244.2 17.6 12.8
1457687_at Bcl2 403.7 400.4 698 818.9 1003.8 1083.6
1460235_at Scarb2 548 497.3 422.2 343.4 686.1 768.7
1460253_at Cmtm7 1517.8 1119.2 1913.9 2176.1 599.7 503.4
1460285_at Itga9 15.6 27.7 69.3 75.1 12.4 18
1460419_a_at Prkcb1 1099.7 1225.6 948.9 830.2 1599.4 1793.6
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Table 6: Genes involved in cytokines, chemokines, and their receptors. The func-
tion related group of 53 IDs was generated using the Database for Annotation, Visualization
and Integrated Discovery (DAVID) and used for Figure 12B.
Affy Number Gene Symbol gut-activated liver-activated naive
1418126_AT Ccl5 404.9 310.2 191.5 64.1 2536.9 1695.7
1418652_AT Cxcl9 1.7 18.2 62.5 45.9 28.9 14.4
1418803_A_AT Tnfsf6 56.7 47.6 88.4 107.4 10.5 2.8
1419083_AT Tnfsf11 101 129.9 188.5 202.2 2 11.6
1419135_AT Ltb 5252.6 5019.3 4050.9 3090.9 6472.6 6305.3
1419307_AT Tnfrsf13c 200.4 209.9 132.6 106.8 111.8 68.5
1419412_AT Xcl1 1121.1 1476.8 1883.9 2299.2 33.9 60.9
1419455_AT Il10rb 734.5 649.3 461.2 331.9 752.8 781.8
1419561_AT Ccl3 95.4 127.6 189.7 149.1 10.9 8.9
1419872_AT Csf1r 30.1 212.5 925.8 416.6 212.4 65.7
1419873_S_AT Csf1r 19.4 58 202.1 109.9 49.9 4.4
1420678_A_AT Il17rb 21.2 4.5 59.6 87.8 21.9 30.6
1420691_AT Il2ra 143.4 80.7 22.1 24.7 16.9 14.5
1420692_AT Il2ra 227.5 140.2 12.9 28.8 7.5 4.5
1420703_AT Csf2ra 34.9 36.3 44.3 67.4 36.3 31.6
1420895_AT Tgfbr1 286.2 247.8 213.6 203.6 548.9 684.2
1420895_AT Tgfbr1 286.2 247.8 213.6 203.6 548.9 684.2
1421034_A_AT Il4ra 212.4 189.2 133 112.9 473.1 562.5
1421207_AT Lif 28.5 51.4 99.4 67.8 1.5 8.2
1421291_AT Il18rap 54.9 84.6 141.5 116.7 51.2 28.1
1421420_AT Gpr2 25.4 8.8 90.4 77.2 24.4 5.4
1421628_AT Il18r1 651.2 319.9 4396.4 4401.9 628.3 434
1421919_A_AT Ccr9 708.7 629 6.6 0.6 323.1 351.3
1421920_A_AT Ccr9 1933 1641.8 12.8 3.9 1022.6 1259.6
1422003_AT Blr1 67.9 92.5 58 41 83.9 58.8
1422231_A_AT Tnfrsf25 56.3 40.2 7.7 1.1 134.4 154.4
1422812_AT Cxcr6 1261.5 920.7 68.5 59.4 832.5 981.7
1422924_AT Tnfsf9 59.3 49.6 103 127.3 28.1 20.9
1424727_AT Ccr5 198.8 135.8 112.1 74.2 93.3 51.3
1425145_AT Il1rl1 55.9 87.2 151.6 182.6 73.4 23.9
1425832_A_AT Cxcr6 1394.3 1196.7 95.7 100.5 837.1 771.8
1426397_AT Tgfbr2 1166.7 1176.2 854.9 637.8 2921.5 3129.4
1427419_X_AT Ccr9 5297.2 4627.2 10.7 15.5 3535.2 3956.3
1433795_AT Tgfbr3 92.2 93.8 6.2 3 213.5 235
1434279_AT Xbp1 96.8 62.6 126 153.2 59.6 37.6
1434310_AT Bmpr2 50.6 59.3 100.3 105.4 63.8 66.1
1437270_A_AT Bsf3 235.9 191.7 164.6 115 655.5 694.7
1448575_AT Il7r 835.8 596.2 175.6 107 4476.4 4477.2
1448576_AT Il7r 209.3 141.2 41.3 23.7 1630.8 1664.7
1448710_AT Cxcr4 204.4 324.6 499.5 638.1 606.7 538.3
1448731_AT Il10ra 71.3 71.6 55.8 43.7 92.3 75.6
1449026_AT Ifnar1 338.8 317.9 254.8 201 368.4 313.1
1449925_AT Cxcr3 2627.7 2398.4 689.7 326.9 454.6 392.9
1450272_AT Tnfsf8 78.1 60.7 149.5 133.9 108.9 87.9
1450298_AT Tnfsf14 118.6 119.8 209 181.6 51.7 50.6
1450357_A_AT Ccr6 102.1 155.4 52.4 47.4 43.7 37.1
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1451462_A_AT Ifnar2 431.4 483.8 636.4 612.2 384.1 309.7
1451944_A_AT Tnfsf11 13.4 19.5 43 47.2 1.6 3.8
1452416_AT Il6ra 91.1 120.8 71.1 39.6 1096.2 1436
1453572_A_AT Plp2 1991.2 2103.7 2898.7 2966.2 637.8 679.9
1455660_AT Csf2rb1 18.6 49.7 116.3 67.2 150.5 108.4
1460220_A_AT Csf1 2.6 14.2 74.1 92.3 9.6 1.9
1460251_AT Tnfrsf6 100.2 105 69.5 51.2 166.3 217.8
Table 7: Genes involved in T-cell activation. The function related group of 87 IDs
was generated using the Database for Annotation, Visualization and Integrated Discovery
(DAVID) and used for Figure 12C.
Affy Number Gene Symbol gut-activated liver-activated naive
1415743_AT Hdac5 128.6 143.2 189 210.2 196.6 175.4
1415907_AT Ccnd3 855.9 711.2 328.8 288.1 830.6 1034.1
1416007_AT Satb1 2887.6 3059.7 1136.4 802.5 5042.7 5763.4
1416008_AT Satb1 2222.7 2347.6 923.4 621.1 3390.6 3507.6
1416034_AT Cd24a 51 132.8 236.2 434.7 920.8 189.1
1417976_AT Ada 186.7 157.7 62.9 51.8 126.5 115.6
1418133_AT Bcl3 209.3 201 94.9 67.1 279.7 419.4
1418340_AT Fcer1g 34 94 322.9 151.6 130.5 68.7
1419128_AT Itgax 153.2 79.6 33.1 23.1 46.4 20.3
1419631_AT Was 1152.8 1134.5 1021.6 883.5 1228.9 1391.7
1419853_A_AT Dnajb9 288.1 164.3 21.8 19.4 63.9 44.6
1420813_AT Hdac7a 562.3 561.8 922.5 1067.8 587.6 653.4
1421140_A_AT Foxp1 443.3 618.3 558.6 726.9 1098 1305
1421141_A_AT Foxp1 527.4 667.9 893.4 958.5 1324.2 1305.7
1421142_S_AT Foxp1 401.5 477.9 607.5 639.2 829.5 953.2
1421173_AT Irf4 538.3 668.2 847.8 771.5 64.5 34.5
1421618_AT Myo1f 407.9 324.5 93.8 11.7 101.6 114.8
1422103_A_AT Stat5b 519.1 505.5 361 310.1 652.5 715.9
1422938_AT Bcl2 71.4 63.6 127.6 133.7 150.4 149.4
1422992_S_AT Pik3cd 408.5 407.9 203.7 136.3 528.5 418.7
1423226_AT Ms4a1 150.6 389.8 68.3 28.2 426.9 243.1
1425335_AT Cd8a 3903.3 3616.8 2422.7 1851.7 2691.8 3023.6
1425396_A_AT Lck 5346.4 5523.5 4715.2 4158.5 5355.8 5865.8
1425515_AT Pik3r1 136.6 158.5 117.5 92.7 289.8 221.3
1425869_A_AT Psen2 432.2 608.9 1125.5 1155 358.1 357.4
1426001_AT Eomes 148.2 217.4 196.5 297.9 576.5 477.4
1426397_AT Tgfbr2 1166.7 1176.2 854.9 637.8 2921.5 3129.4
1426538_A_AT Trp53 107.8 66.2 150.2 175.2 39.2 38.1
1427301_AT Cd48 5227.5 4994.6 3405.5 2756.1 2875.9 2826.5
1427739_A_AT Trp53 167 131.9 177.2 195.1 98.5 96
1429477_AT D15Ertd785e 129 114.1 156.9 164.1 118.1 99.2
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1429524_AT Myo1f 984.9 874.4 227.2 84.9 249.4 205.4
1429525_S_AT Myo1f 975.2 813.7 242.2 87.5 275 253
1432459_A_AT Rog 451.3 392.7 1269.5 922.4 3.8 23.3
1434279_AT Xbp1 96.8 62.6 126 153.2 59.6 37.6
1435222_AT Foxp1 930.6 1086.7 1314.6 1403.4 2064.8 2329.9
1435227_AT Bcl11b 1555.7 1481 964 868.6 3201.8 3264.7
1435272_AT Itpkb 350.7 277.7 438 357.3 507.2 583.1
1435477_S_AT Fcgr2b 25.9 83.3 200.6 66.7 96.2 17.2
1436182_AT Satb1 624.1 775.4 265.8 153.4 1355.8 1417
1436423_AT Themis 772.2 753.8 207.6 236.4 1223.9 1351.9
1437122_AT Bcl2 124.7 133.2 175.9 261.3 427.7 476.4
1437270_A_AT Bsf3 235.9 191.7 164.6 115 655.5 694.7
1437304_AT Cblb 375.1 488.1 1096.8 920.1 289.1 318
1437502_X_AT Cd24a 41 108 216.4 305.2 1033.4 366.9
1437504_AT Sla2 178.9 181.8 93.5 81.6 270.2 320.9
1438682_AT Pik3r1 668.9 698.4 514.7 426.3 1396.3 1426.1
1438784_AT Bcl11b 373.1 309.7 220.6 227 695.5 560.8
1438802_AT Foxp1 87.3 81.9 119.4 185.3 161.6 142.4
1439449_AT Satb1 71.7 57.9 47.4 37.3 117.4 121.3
1439719_AT Themis 273.7 222.8 34.9 61.5 249.1 263.7
1439787_AT Dnajb9 524.6 359.9 31.2 34.5 115.6 124.2
1440708_AT Myh9 81.9 53 100.5 140.5 63.1 56.7
1440770_AT Bcl2 81.8 68.3 131 225.1 166.8 157.5
1440811_X_AT Cd8a 958.3 875.6 612.7 472.9 847.3 941
1441058_AT Itpkb 65.2 77.3 141.2 259.3 135 132.3
1442022_AT Themis 126.3 122 46.2 34.5 100.1 100.8
1442233_AT Fyb 114.1 111.8 169.4 196.7 216 169.7
1443284_AT Satb1 75 66.3 34.9 29 109.6 88.1
1443837_X_AT Bcl2 76.2 59 138.4 176 131.6 156.3
1444078_AT Cd8a 2823.2 2780.2 2090.4 1336.8 3455.1 4011.8
1447209_AT Foxp1 28.3 39.9 47.5 79 143.7 118.9
1448182_A_AT Cd24a 128.8 292.5 585 889.7 2182.7 607.2
1448436_A_AT Irf1 1102.3 945.9 714.1 503.5 1921.2 2177
1448575_AT Il7r 835.8 596.2 175.6 107 4476.4 4477.2
1448576_AT Il7r 209.3 141.2 41.3 23.7 1630.8 1664.7
1448620_AT Fcgr3 26.7 63.6 138.4 50.2 41.9 15.1
1448710_AT Cxcr4 204.4 324.6 499.5 638.1 606.7 538.3
1449026_AT Ifnar1 338.8 317.9 254.8 201 368.4 313.1
1449131_S_AT Cd1d1 263.7 271.6 207.5 157.6 428 466.9
1450339_A_AT Bcl11b 953.6 805.7 584.3 544.2 1742.7 2162.6
1450495_A_AT Klrk1 850.9 671 2134.4 1681.5 71.3 45.2
1450912_AT Ms4a1 45.8 136.2 23.6 8.6 270.7 135.2
1451492_AT Sla2 286.3 264.1 197.1 141.7 321.1 390.6
1451673_AT Cd8a 3619.9 3028.6 2508.6 1996.1 1663.1 1583.3
1451780_AT Blnk 18.1 82.3 20.1 6 147.7 45.1
1452966_AT Bcl11b 420.1 341.1 259.6 178.8 727.7 840.1
1453281_AT Pik3cd 1411.5 1273.7 734.8 649.6 1694.2 1922.9
1453361_AT Hells 66.3 45.9 120.1 118.2 17.7 17.7
1453851_A_AT Gadd45g 156.9 158.2 52.1 53.7 130.7 193.5
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1454960_AT Madh3 356.9 296.5 184.3 174.8 486.2 475.1
1455082_AT Cblb 649 765.4 1420 1322.6 582.7 586.1
1456174_X_AT Ndr1 116.3 158 69.1 56 104.7 147.5
1456429_AT Malt1 155.8 161.7 201.4 218.1 263.3 202.1
1457687_AT Bcl2 403.7 400.4 698 818.9 1003.8 1083.6
1458469_AT Cblb 199.2 193 595.1 976.1 203.6 188
1460651_AT Lat 3021.9 2870.5 1894.3 1893.5 3196.1 3755.2
Table 8: Genes involved in apoptosis. The function related group of 122 IDs was
generated using the Database for Annotation, Visualization and Integrated Discovery (DAVID)
and used for Figure 12D.
Affy Number Gene Symbol gut-activated liver-activated naive
1415910_S_AT Ciapin1 372.7 395.4 525.7 524 206.1 192.2
1416000_A_AT Prdx1 4614.6 4935.6 3865.1 3916.9 3296.1 3668.6
1416034_AT Cd24a 51 132.8 236.2 434.7 920.8 189.1
1416271_AT Perp 76.7 55.1 111.4 106.7 0.6 2.6
1416303_AT Litaf 311.9 439 827.4 694 143.3 116.2
1416304_AT Litaf 156.2 162.4 340.7 338.6 37.2 23.9
1416406_AT Pea15 123.5 94.6 66.3 40.1 140.8 191.5
1416407_AT Pea15 166.8 196.1 115.3 112.9 269 280.8
1416505_AT Nr4a1 192.7 326.8 479.4 681.1 146.6 167.6
1416813_AT Tia1 261.4 228 294.7 350.8 203.2 155.4
1416950_AT Tnfaip8 913.5 945.2 1223.3 1281.3 1127.5 1335.1
1416961_AT Bub1b 584.9 568.5 702.5 766.2 78 31.8
1417346_AT Asc 2984.5 3116 2471.8 2206.8 1812.7 2180.6
1417756_A_AT Lsp1 3143.8 2704.3 2732.9 2006.8 1846.7 2199.8
1417898_A_AT Gzma 9778.7 8379.4 261.4 41.9 953.4 409.9
1418110_A_AT Inpp5d 386.5 348.3 240.4 316 433.4 527.1
1418133_AT Bcl3 209.3 201 94.9 67.1 279.7 419.4
1418203_AT Pmaip1 302.9 250.5 390.6 512.7 163.2 160
1418626_A_AT Clu 1.9 9.6 44.9 157.9 15.6 6.3
1418649_AT Egln3 106.5 112.7 26.5 27.6 35.7 71.7
1418803_A_AT Tnfsf6 56.7 47.6 88.4 107.4 10.5 2.8
1418840_AT Pdcd4 2411.5 2588.3 1872.3 1810.7 3450.3 3876.3
1419060_AT Gzmb 7617.9 5069.6 451.6 291 154.8 87
1419135_AT Ltb 5252.6 5019.3 4050.9 3090.9 6472.6 6305.3
1420499_AT Gch 170.9 191.5 348.4 338.4 169.7 206.4
1420691_AT Il2ra 143.4 80.7 22.1 24.7 16.9 14.5
1420692_AT Il2ra 227.5 140.2 12.9 28.8 7.5 4.5
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1420895_AT Tgfbr1 286.2 247.8 213.6 203.6 548.9 684.2
1420932_AT Mapk8 116.7 101.9 157.3 163.7 84.2 90.5
1421027_A_AT Mef2c 22.3 59 8.3 11.5 101.4 31.6
1421066_AT Jak2 643.3 627.9 498.1 425.9 652.7 672.8
1422005_AT Prkr 269.6 335.1 109.2 77.7 256.4 173.6
1422006_AT Prkr 197.6 191.7 97.6 88.1 100 79.5
1422631_AT Ahr 79.6 71.2 33 23.8 45.2 49.4
1422938_AT Bcl2 71.4 63.6 127.6 133.7 150.4 149.4
1423790_AT Dap 777.1 762.2 1017.1 1034.3 671.7 635.1
1423986_A_AT Scotin 4801.7 4946.4 4250 3724.3 4960.4 5243.4
1424850_AT Map3k1 249.9 265.7 410.8 367.7 435.5 467.7
1425396_A_AT Lck 5346.4 5523.5 4715.2 4158.5 5355.8 5865.8
1425419_A_AT Raf1 1059.8 1222.1 939.4 822.5 804.2 754.3
1425869_A_AT Psen2 432.2 608.9 1125.5 1155 358.1 357.4
1426165_A_AT Casp3 293.3 217.6 506.2 428.8 67.8 27.8
1426184_A_AT Pdcd6ip 82.5 70.2 54.7 37 187.5 170.2
1426313_AT Bre 337.9 315.2 474.5 406.1 227.9 164.8
1426538_A_AT Trp53 107.8 66.2 150.2 175.2 39.2 38.1
1427064_A_AT AI118201 124.5 143.7 190.6 213.6 156.1 160.7
1427442_A_AT App 15 70.9 121.8 45.3 242.6 180.5
1423790_AT Dap 777.1 762.2 1017.1 1034.3 671.7 635.1
1423986_A_AT Scotin 4801.7 4946.4 4250 3724.3 4960.4 5243.4
1424850_AT Map3k1 249.9 265.7 410.8 367.7 435.5 467.7
1425396_A_AT Lck 5346.4 5523.5 4715.2 4158.5 5355.8 5865.8
1425419_A_AT Raf1 1059.8 1222.1 939.4 822.5 804.2 754.3
1425869_A_AT Psen2 432.2 608.9 1125.5 1155 358.1 357.4
1426165_A_AT Casp3 293.3 217.6 506.2 428.8 67.8 27.8
1426184_A_AT Pdcd6ip 82.5 70.2 54.7 37 187.5 170.2
1426313_AT Bre 337.9 315.2 474.5 406.1 227.9 164.8
1426538_A_AT Trp53 107.8 66.2 150.2 175.2 39.2 38.1
1427064_A_AT AI118201 124.5 143.7 190.6 213.6 156.1 160.7
1427442_A_AT App 15 70.9 121.8 45.3 242.6 180.5
1427739_A_AT Trp53 167 131.9 177.2 195.1 98.5 96
1428433_AT Hipk2 116.4 164.9 79.7 82.4 448 366.1
1428842_A_AT Ngfrap1 718.1 698.6 932.6 760.9 459.1 413.7
1429734_AT 4632434I11Rik 68.4 59.4 113.7 106.6 30.9 12.6
1430165_AT Stk17b 490 405.2 673 850.1 742.8 721.2
1430192_AT Casp3 47.5 35 80.9 77.3 23.8 9
1430705_AT Puf60 53.8 37.1 75.4 99.1 57.2 42.3
1431708_A_AT Tia1 94.3 106.8 147.8 176.6 163.1 127.2
1432466_A_AT Apoe 34.6 143.9 208.9 584.4 62.2 75.4
1433428_X_AT Tgm2 5.1 27.2 281.1 85.3 77.1 24.8
1433699_AT Tnfaip3 253.2 281.9 389.3 525.6 489.6 484.9
1433757_A_AT Nisch 190.8 154.5 234.2 260.4 489 420
1433758_AT Nisch 137.1 115.6 171.2 181.8 263.5 255.2
1434279_AT Xbp1 96.8 62.6 126 153.2 59.6 37.6
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1434557_AT Hip1 89.2 80.4 51.9 37.4 14.6 2.8
1434699_AT G2e3 196.1 172.1 257.3 263.9 141.2 125.3
1434700_AT G2e3 195.1 182.8 256.9 271.3 131.4 151
1435448_AT Bcl2l11 1326.7 1380.8 1052.9 792.7 628.6 590.2
1437122_AT Bcl2 124.7 133.2 175.9 261.3 427.7 476.4
1437277_X_AT Tgm2 9.3 44.8 210 67.4 59.3 30.3
1437393_AT AI875142 206.2 255.3 461.1 447 294.8 255.4
1437502_X_AT Cd24a 41 108 216.4 305.2 1033.4 366.9
1437532_AT Rnf216 113.8 84.5 142.7 164.9 55 40.2
1437594_X_AT Pigt 175.3 164.6 128.9 116.2 216.3 244.3
1437689_X_AT Clu 0.2 1.2 76.1 275.5 2.1 2.2
1437862_AT Rbm25 483.6 397.2 766.9 901.1 647 545.3
1438069_A_AT Rbm5 98.1 69.7 130.5 133.2 198.8 142.3
1438553_X_AT 4930453N24Rik 109.4 156.1 67.6 67 174.2 298.6
1440275_AT Runx3 1091.9 987.7 697.3 535.2 810.2 1033.7
1440533_AT Bfar 43.2 35.4 54 66.2 99.5 73.7
1440770_AT Bcl2 81.8 68.3 131 225.1 166.8 157.5
1440866_AT EIF2AK2 243.5 232.2 99.3 75 150.6 139.5
1441943_X_AT Ciapin1 169.4 128.4 189.2 202.8 129 155.7
1443540_AT Map3k1 42.8 32.9 91.7 65.2 35.7 23.1
1443698_AT Xaf-1 1349.9 1377.4 630.4 280.5 918.4 870.3
1443837_X_AT Bcl2 76.2 59 138.4 176 131.6 156.3
1443856_AT Nup88 96.1 111.6 125.8 125.6 104.4 116.9
1445395_AT Prkca 17.7 3.5 44.9 88.3 22.7 9.7
1445452_AT Traf1 423.1 384.6 536.3 631.4 355.1 245.1
1447363_S_AT Bub1b 732.6 715.5 884.4 992.4 75.7 42.6
1448140_AT Ciapin1 167.2 157.7 176.6 211.4 105.7 101.4
1448155_AT Pdcd6ip 367.5 416.2 325.4 271.5 762.7 757.2
1448182_A_AT Cd24a 128.8 292.5 585 889.7 2182.7 607.2
1448620_AT Fcgr3 26.7 63.6 138.4 50.2 41.9 15.1
1449193_AT Cd5l 13.2 61 882.5 371.6 31.8 15.7
1449235_AT Tnfsf6 143.8 116.1 190.8 229 21.8 14.4
1449317_AT Cflar 152.2 122.1 186.6 190.9 101 96.3
1449523_AT Bcl7c 209.3 184.3 269.8 330.7 188.4 178.5
1449674_S_AT Pdcd6ip 675.1 653.8 451.8 471.2 1023.8 1298.5
1449773_S_AT Gadd45b 98.2 112.6 50.5 46.8 117.4 124.1
1449835_AT Pdcd1 419.8 628.7 824.2 961 23.8 31.4
1449839_AT Casp3 1386.9 1407.4 2168.8 2061.2 354.7 238.2
1450112_A_AT Gas2 70.3 94.1 138.8 151.8 19.3 12.8
1450945_AT Prkca 148.7 142.9 226.2 282.7 47.9 34.8
1450971_AT Gadd45b 267.1 219.8 40.3 48.8 203.7 173.2
1451112_S_AT Dap 1944.3 1877.9 2328 2390.3 1706.3 1696.9
1451485_AT Luc7l3 1546.8 1199.6 1841.6 1786.5 1315.9 1287.7
1451767_AT Ncf1 160 211.1 28.1 7.5 124.2 83.3
1452070_AT Dedd2 297.7 323.8 178.4 215.7 272.4 223.7
1453568_AT Dapl1 1896.4 1684.4 4713.7 3561.7 3541.9 2991.6
1453851_A_AT Gadd45g 156.9 158.2 52.1 53.7 130.7 193.5
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1454733_AT Card4 238.9 203.9 129 82.2 367.1 351.3
1455355_AT G2e3 129 126.4 179.7 245.6 38 33.6
1455900_X_AT Tgm2 15.2 39.4 172.8 64.7 64.7 32.2
1456005_A_AT Bcl2l11 2585.5 2669.2 2133.7 1591.6 1110.3 1018.9
1456022_AT Hipk2 115.6 108.5 71.9 41.2 289.3 265.7
1456071_A_AT Cycs 7125.2 7475.3 6065.8 5960 5244.6 5305.3
1456262_AT Rbm5 149.1 121.1 168.9 275.1 202.5 186.1
1456429_AT Malt1 155.8 161.7 201.4 218.1 263.3 202.1
1456772_AT Ncf1 498.7 635.8 145 52.1 399.8 340
1456950_AT Alms1 46.1 35.8 73.1 69.5 41.8 19
1457687_AT Bcl2 403.7 400.4 698 818.9 1003.8 1083.6
1460251_AT Tnfrsf6 100.2 105 69.5 51.2 166.3 217.8
1460710_AT Adora2a 205.1 236.4 268.8 333.6 135.5 105.1
1460718_S_AT Mtch1 431.2 427.6 299.5 299 204.2 203.5
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